[vc_row][vc_column width=”1/4″]
[/vc_column][vc_column width=”3/4″]
Professor Maria Isabel Lucena, MD PhD, Spain
H-index 44
Professor M. Isabel Lucena has been appointed as an excellent candidate due to the outstanding and continued achievements in the field of Clinical Pharmacology.
Professor M. Isabel Lucena has a degree in Medicine at Granada University, and a 3-year specialist training in clinical pharmacology and therapeutics (1980-1983). In 1980 she obtained a PhD in Medicine and Surgery. Her teaching experience is extended to more than 35 years, from under graduate students to post-graduate student
Prof. Dr M. Isabel Lucena main research area of interest is the study of drug-induced liver injury (DILI), an area where she has led an intensive research and gathered an extensive knowledge that has granted her an international prominent leading position in the field. Professor Dr. M. Isabel Lucena works in close collaboration with international groups in this field. The results of this intensive work are documented in more than 300 publications in peer-reviewed journals and more than 20 book chapters. She has an H-index of 44 and 6444 citations. She has directed 25 PhD thesis included 3 International theses.
She founded and coordinates the Spanish DILI Registry (www.spanishdili.uma.es), a successful initiative that was followed by the foundation of the Spanish Latin-American DILI Network, and more recently the Prospective European DILI Registry awarded by EASL.
Professor Dr. M. Isabel Lucena is currently Scientific Director of the Clinical Pharmacology Service at the University Hospital of Malaga and Scientific coordinator of SCReN, the Platform of Clinical research and clinical trials at IBIMA. 2013-). She is currently member of the Executive Committee of the International Union of Basic and Clinical Pharmacology and Treasurer of the Clinical pharmacology division of IUPHAR.
Prof. M. Isabel Lucena is a genuine reference for all clinical pharmacologists due to her strong dedication to research and outstanding contribution to increase the knowledge in the field of drug induced liver injury; a major drug safety problem faced in daily clinical practice. She is a model of commitment with the collaborative multidisciplinary research and the dissemination of knowledge. She is an inspiring clinical pharmacologist, who keeps a strong scientific and teaching activity in clinical pharmacology.
[/vc_column][/vc_row]
[vc_row][vc_column]
[wm_tabs active=”1″ ]
[wm_item title=”Nomination Letter”]
We are pleased to nominate Prof. Dr. M. Isabel Lucena-González for the EACPT 2021 Lifetime Achievement Award in Clinical Pharmacology. Professor M. Isabel Lucena has been unanimously appointed by all members of the Executive Committee of the Spanish Society of Clinical Pharmacology as an excellent candidate due to the outstanding and continued achievements in the field of Clinical Pharmacology.
Maria-Isabel Lucena is Professor of Clinical Pharmacology and has a degree in Medicine at Granada University, and a 3-year specialist training in clinical pharmacology and therapeutics. In 1980 she obtained a PhD in Medicine and Surgery, with an excellent cum laude qualification and the outstanding doctorate distinction. In 1986 she was granted a full professor degree at Malaga University, where she continues actively teaching medical students as Director of the Pharmacology&Paediatrics Department (School of Medicine, University of Malaga). Her teaching experience is extended to more than 35 years, from under graduate students to post-graduate students. She has been responsible for the clinical pharmacology doctorate program and tutor in charge of clinical pharmacology training physicians during the past 30 years.
Prof. Dr M. Isabel Lucena main research area of interest is the study of drug-induced liver injury (DILI), an area where she has led an intensive research and gathered an extensive knowledge that has granted her an international prominent leading position in the field. Her main lines of research are epidemiological in DILI, the assessment of causality, stratification of risk and mechanistic factors: genetics and immunophenotyping studies, other omics and clinical trials design in order to improve the mechanistic understanding of DILI and the development of novel biomarkers and their transfer into clinical practice.
Professor Dr. M. Isabel Lucena works in close collaboration with international groups in this field and she belongs to CIBERehd, the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) and leads the PAIDI CTS-649 group. She is the co-investigator of IBIMA Group on Hepatogastroenterology, Pharmacology and Translational Clinical Pharmacology. She is Rapporteur of CIOMS working Group on Drug-Induced Liver Injury (DILI). Member of the Reviewing board & organizer of the Post-Graduate Course on Lifestyle and Liver Diseases for the European Association for the Study of the Liver (EASL International Liver Congress (2016-). Prof. M. Isabel Lucena is actually co-director of the EASL Postgraduate Course 2021.
Prof. M. Isabel Lucena also participates in relevant International collaborations in the field: partners in the IMI Safer and Faster Evidence Based Translation consortium (SAFE-T, 2008-2015), the International Serious Adverse Event Consortium (iSAEC), IMI2 TRANSBIOLINE project (2019-), Eurostars Programme: Novel Combo Assay for Early Detection of DILI (E!114589-LiverAce. 2021-) and leading the COST Action 17112 Prospective European Drug-Induced Liver Injury Network 2 (https://proeurodilinet.eu). Collaboration with Prof Kaplowitz (South California U), Susuki at Duke U, Aithal (Nottingham) and Chen M (National Centre for Toxicological Research-FDA).
With the aim to increase knowledge in the field, she founded and coordinates the Spanish DILI Registry (www.spanishdili.uma.es), a successful initiative that was followed by the foundation of the Spanish Latin-American DILI Network, and more recently the Prospective European DILI Registry awarded by EASL.
Some of these achievements are the outcome of a close and fruitful collaboration with clinical experts in the field, which should serve as an inspiring example of the value of the multidisciplinary collaborative work for the clinical pharmacology community.
Due to her outstanding knowledge in the field, she also collaborates actively with the European regulators like the Spanish Medicines and Medical devices Agency (AEMPS) and the European Medicines Agency (EMA), as an expert consultant on drug-induced liver injury and related issues.
She is frequently invited as speaker in national and international conferences, workshops, training courses and all type of meetings related to her area of interest and research, i.e. drug induced liver injury, accounting for more than 100 lectures and more than 350 works presented up to date.
The results of this intensive work is documented in more than 300 publications in peer-reviewed journals and more than 20 book chapters. She has an H-index of 44 and 6444 citations. 15 publications were cited more than 100 times and 37 original articles received more than 50 citations. She has directed 25 PhD thesis included 3 Internacional thesis, 5 Extraordinary awards and 1 doctoral thesis co-tutelled with the University of Maastricht, Germany (defense 12thFeb.21), including also 11 final medical degree research projects.
This intensive research experience has led Professor Dr. M. Isabel Lucena to accept the current position of Scientific Director of the Clinical Pharmacology Service at the University Hospital of Malaga and Scientific coordinator of SCReN, the Platform of Clinical research and clinical trials at IBIMA (since 2013-). She was former Vice-director (2010-2013) and Scientific Director / Founder of IBIMA (Malaga Health Research Institute) (2013-2017).
She is also an active member of several professional societies. She is member of the Executive Committee of the International Union of Basic and Clinical Pharmacology. Treasurer of the Clinical pharmacology division of IUPHAR. She is member of the EACPT and places an active role in EACPT Congresses and EACPT summer courses. She is member of the SEFC, and has also been member of the Executive Committee of the Spanish Clinical Pharmacology Society (SEFC).
The Spanish Society of Clinical Pharmacology considers Prof. M. Isabel Lucena a genuine reference for all clinical pharmacologists due to her strong dedication to research and outstanding contribution to increase the knowledge in the field of drug induced liver injury; a major drug safety problem that most clinical pharmacologists face in our daily clinical practice. She is a model of well-done hard work, passion and never ending enthusiasm, commitment with the collaborative multidisciplinary research and the dissemination of knowledge. In summary, she is an inspiring clinical pharmacologist for all of us.
We are proud to nominate a candidate who keeps a strong scientific and teaching activity in clinical pharmacology and that plans to continue doing so as long as she is allowed.
Yours sincerely,
On behalf of the Executive Committee of the Spanish Society of Clinical Pharmacology
Dr. Antonia Agustí,
President of the SEFC
The nomination letter was signed by Dr. Antonia Agustí, President of SEFC
Madrid, 15th February 2021
view original nomination letter
[/wm_item]
[wm_item title=”Curriculum Vitae”]
Maria Isabel Lucena, MD, PhD
DATE OF BIRTH: 21 August, 1956
PLACE OF BIRTH: Málaga
NATIONALITY : Spain
STATUS: married, 3 children
QUALIFICATIONS
Degree in Medicine and Surgery, University of Málaga, 1980
Doctorate in Medicine (PhD). University of Granada, 1983. Excellent, cum lauden
MEMBERSHIP OF SOCIETIES
Member of the Executive Committee of the International Union of Basic and Clinical Pharmacology. Treasurer of the Clinical pharmacology division of IUPHAR.
Member of the European Association for Clinical Pharmacology and Therapeutics (EACPT).
Member of the SEFC, past member of the Executive Committee of the Spanish Clinical Pharmacology Society (SEFC).
HONOURS
Member of the Editorial Board of Hepatology (2012-2016) (D1)
Member of the Editorial Board of Frontiers in Pharmacology (Q1).
Member of Belongs to CIBERehd, the European Network of Centres for Pharmacoepidemiology and Pharmacovigilance (ENCePP) and leads the PAIDI CTS-649 group.
Co-IP of IBIMA Group on Hepatogastroenterology, Pharmacology and Translational Clinical Pharmacology.
PRESENT EMPLOYMENT
University of Malaga, Spain.
OTHER ACTIVITIES
Past
Vice-director (2010-2013) and Scientific Director / Founder of IBIMA (Malaga Health Research Institute) (2013-2017).
Current
Scientific coordinator of SCReN, Platform of Clinical research and clinical trials at IBIMA (2013-).
Director of the Pharmacology&Paediatrics Department (School of Medicine, University of Malaga).
Co-director EASL Postgraduate Course (2021).
Funder and coordinator of the Spanish DILI Registry (www.spanishdili.uma.es) and of the Spanish Latin-American DILI Network; and of the Prospective European DILI Registry awarded by EASL.
DETAILS OF PREVIOUS EMPLOYMENT
Biomedical Research Institute, Malaga (IBIMA) 2012-2013
Universidad de Granada. Assistant Professor (1982-1983)
Universidad de Málaga. Assistant Professor (1983-86)
ADDITIONAL TRAINING
University Hospital San Cecilio, (1980-83). Training in Clinical Pharmacology.
EDUCATIONAL ACTIVITIES
See attached CV.
CONSULTANCY
Rapporteur of CIOMS working Group on Drug-Induced Liver Injury (DILI).
Member of the Reviewing board & organizer of the Post-Graduate Course on Lifestyle and Liver Diseases for the European Association for the Study of the Liver (EASL International Liver Congress (2016-).
Expert of the AEMPS (collaboration agreement 1999-) and the European Medicines Agency on liver safety.
[/wm_item]
[wm_item title=”Publications”]
full list of publications
Maribel Lucena has been an author of more than 340 publications and book chapters, including more than 300 articles in peer-review journals. She has an H-index of 44 and 6444 citations.
1 CAMILLA STEPHENS; MERCEDES ROBLES-DIAZ; INMACULADA MEDINA-CALIZ; MIREN GARCIA-CORTES; AIDA ORTEGA-ALONSO; JUDITH SANABRIA-CABRERA; ANDRES GONZALEZ-JIMENEZ; ISMAEL ALVAREZ-ALVAREZ; MAHMOUD SLIM; MIGUEL JIMENEZ-PEREZ; ROCIO GONZALEZ-GRANDE; M CARMEN FERNANDEZ; MARTA CASADO; GERMAN SORIANO; EVA ROMAN; HACIBE HALLAL; MANUEL ROMERO-GOMEZ; AGUSTIN CASTIELLA; ISABEL CONDE; MARTIN PRIETO; JOSE MARIA MORENO-PLANAS; ALVARO GIRALDEZ; J MIGUEL MORENO-SANFIEL; NEIL KAPLOWITZ; M ISABEL LUCENA; RA.L J ANDRADE.. Comprehensive analysis and further insights gained from the long-term experience of the Spanish DILI Registry.Journal of Hepatalogy (D1: 2/88) CORRESPONDING AUTHOR. ELSEVIER, 2021. ISSN 0168-8278 DOI: 10.1016/j.jhep.2021.01.029.
2 FERNANDO BESSONE; NELIA HERNANDEZ; MANUEL MENDIZABAL; EZEQUIEL RIDRUEJO; GISELA GUALANO; EDUARDO FASSIO; MIRTA PERALTA; HUGO FAINBOIM; MARGARITA ANDERS; HUGO TANNO; FEDERICO TANNO; RAYMUNDO PARANA; INMACULADA MEDINA-CALIZ; MERCEDES ROBLES-DIAZ; ISMAEL ALVAREZ-ALVAREZ; HAO NIU; CAMILLA STEPHENS; LUIS COLOMBATO; MARCO ARRESE; M VIRGINIA REGGIARDO; SUZANE KIOKO ONO; FLAIR CARRILHO; M ISABEL LUCENA; RAUL J ANDRADE..Serious liver injury induced by Nimesulide: an international collaboration study reporting 57 cases.Archives of Toxicology (D1: 9/92) ACCEPTED FOR PUBLICATION – SHARE SENIOR AUTHORSHIP. 2021. ISSN 0340-5761
3 WEERSINK RA; ALVAREZ-ALVAREZ I; MEDINA-C.LIZ I; SANABRIA-CABRERA J; ROBLES-D.AZ M; ORTEGAALONSO A; GARC.A-CORT.S M; BONILLA E; NIU H; SORIANO G; JIMENEZ-PEREZ M; HALLAL H; BLANCO S; KAPLOWITZ N; LUCENA MI; ANDRADE RJ.. Clinical characteristics and outcome of drug-induced liver injury in the older patients: from the young-old to the oldest-old.Clinical Pharmacology & Therapeutics (D1: 16/271) CORRESPONDING AUTHOR. WILEY, 2020. ISSN 0009-9236 DOI: 10.1002/cpt.2108
4 RIVERA P; VARGAS A; PASTOR A; BORONAT A; L.PEZ-GAMBERO AJ; S.NCHEZ-MAR.N L; MEDINA-VERA D; SERRANO A; PAV.N FJ; DE LA TORRE R; AGIRREGOITIA E; LUCENA MI; RODR.GUEZ DE FONSECA F; DECARA J; SU.REZ J.. Differential hepatoprotective role of the cannabinoid CB1 and CB2 receptors in paracetamol-induced liver injury.British Journal of Pharmacology (D1: 9/270). 177 – 14, pp. 3309 – 3326. WILEY, 2020.ISSN 0007-1188 DOI: 10.1111/bph.15051
5 NICOLETTI P; DEVARBHAVI H; GOEL A; VENKATESAN R; EAPEN CE; GROVE JI; ZAFER S; BJORNSSON E; LUCENA MI; ANDRADE RJ; PIRMOHAMED M; WADELIUS M; LARREY D; MAITLAND-VAN DER ZEE AH; IBANEZ L; WATKINS PB; DALY AK; AITHAL GP.. Genetic risk factors in drug-induced liver injury due to isoniazid-containing anti-tuberculosis drug regimens.Clinical Pharmacology & Therapeutics (D1: 16/270) IN PRESS. WILEY, 2020. ISSN 0009-9236 DOI: 10.1002/cpt.2100
6 ZOUBEK MIGUEL; LUCENA GONZ.LEZ MAR.A ISABEL; ANDRADE RA.L; STEPHENS CAMILLA. Systematic review: Ibuprofen-induced liver injury.Alimentary Pharmacology & Therapeutics (D1: 11/271; CORRESPONDING AUTHOR). 51 – 6, pp. 603 – 611. WILEY, 2020. ISSN 0269-2813 DOI: 10.1111/apt.15645
7 CIRULLI ET; NICOLETTI P; ABRAMSON K; ANDRADE RJ; BJORNSSON ES; CHALASANI N; FONTANA RJ; HALLBERG P; LI YJ; LUCENA MI; LONG N; MOLOKHIA M; NELSON MR; ODIN JA; PIRMOHAMED M; RAFNAR T; SERRANO J; STEF.NSSON K; STOLZ A; DALY AK; AITHAL GP; WATKINS PB.. A Missense Variant in PTPN22 is a Risk Factor for Drug-induced Liver Injury.Gastroenterology (D1: 4/88). 156 – 6, pp. 1707 – 1716. W B SAUNDERS CO-ELSEVIER INC, 2019. ISSN 0016-5085 DOI: 10.1053/j.gastro.2019.01.034
8 PAOLA NICOLETTI; GURUPRASAD AITHAL; THOMAS CHAMBERLAIN; SALLY COULTHARD; MOHAMMAD ALSHABEEB; JANE GROVE; RAUL ANDRADE; EINAR BJORNSSON; JOHN DILLON; PAR HALLBERG; M. ISABEL LUCENA; ANKE-HILSE MAITLAND-VAN DER ZEE; JENNIFER MARTIN; MARIAM MOLOKHIA; MUNIR PIRMOHAMED; MIA WADELIUS; YUFENG SHEN; MATT NELSON; AND ANN DALY.. Drug-induced injury due to flucloxacillin: relevance of multiple HLA alleles.Clinical Pharmacology & Therapeutics (D1: 16/270). 106 – 1, pp. 245 – 253. WILEY, 2019. ISSN 0009-9236 DOI: 10.1002/cpt.1375
9 TORRES S; BAULIES A; INSAUSTI-URKIA N; ALARC.N-VILA C; FUCHO R; SOLSONA-VILARRASA E; N..EZ S; ROBLES D; RIBAS V; WAKEFIELD L; GROMPE M; LUCENA MI; ANDRADE RJ; WIN S; AUNG TA; KAPLOWITZ N; GARC.A-RUIZ C; FERN.NDEZ-CHECA JC.. Endoplasmic Reticulum Stress-Induced Upregulation of STARD1 Promotes Acetaminophen-Induced Acute Liver Failure.Gastroenterology (D1: 4/88). 157 – 2, pp. 552 – 568. W B SAUNDERS CO-ELSEVIER INC, 2019. ISSN 0016-5085 DOI: 10.1053/j.gastro.2019.04.023
10 NICOLETTI P; BARRETT S; MCEVOY L; DALY AK; AITHAL G; LUCENA MI; ANDRADE RJ; WADELIUS M; HALLBERG P; STEPHENS C; BJORNSSON ES; FRIEDMANN P; KAINU K; LAITINEN T; MARSON A; MOLOKHIA M; PHILLIPS E; PICHLER W; ROMANO A; SHEAR N; SILLS G; TANNO LK; SWALE A; FLORATOS A; SHEN Y; NELSON MR; WATKINS PB; DALY MJ; MORRIS AP; ALFIREVIC A; PIRMOHAMED M.. Shared Genetic Risk Factors Across Carbamazepine-Induced Hypersensitivity Reactions.Clinical Pharmacology & Therapeutics (D1: 15/267). 106 – 5, pp. 1028 – 1036. WILEY, 2019. ISSN 0009-9236 DOI: 10.1002/cpt.1493
11 Medina-Caliz I; Garcia-Cortes M; Gonzalez-Jimenez A; Cabello MR; Robles-Diaz M; Sanabria-Cabrera J; Sanjuan-Jimenez R; Ortega-Alonso A; Garc.a-Mu.oz B; Moreno I; Jimenez-Perez M; Fernandez MC; Gin.s P; Prieto M; Conde I; Hallal H; Soriano G; Roman E; Castiella A; Blanco-Reina E; Montes MR; Quiros-Cano M; Martin-Reyes F; Lucena MI; Andrade RJ. Herbal and Dietary Supplement-induced Liver Injuries in the Spanish DILI Registry. Clinical Gastroenterology and Hepatology (D1, 8 of 84; CORRESPONDING AUTHOR). 16 – 9, pp. 1495 – 1502. ELSEVIER
12 Zoubek ME; Gonzalez-Jimenez A; Medina-C.liz I; Robles-D.az M; Hernandez N; Romero-G.mez M; Bessone F; Hallal H; Cubero FJ; Lucena MI; Stephens C; Andrade RJ. High Prevalence of Ibuprofen Drug-Induced Liver Injury in Spanish and Latin-American Registries.Clin. Gastroenterol. Hepatol. (D1, 8 of 84; CORRESPONDING AUTHOR).16 – 2, pp. 292 – 294. ELSEVIER SCIENCE INC, 2018. ISSN 1542-3565 DOI: 10.1016/j.cgh.2017.07.037
13 Wadelius M; Eriksson N; Kreutz R; Bondon-Guitton E; Iba.ez L; Carvajal A; Lucena MI; Sancho Ponce E; Molokhia M; Martin J; Axelsson T; Kohnke H; Yue QY; Magnusson PKE; Bengtsson M; Hallberg P; EuDAC. Sulfasalazine-Induced Agranulocytosis Is Associated With the Human Leukocyte Antigen Locus. Clinical pharmacology and therapeutics (D1, 15 of 267). 103 – 5, pp. 843 – 853. WILEY, 2018. ISSN 0009-9236 DOI: 10.1002/cpt.805 Tipo de producción:
14 Mart.nez-Chantar ML; Delgado TC; Mato JM; Lu SC; Varela-Rey M; Andrade R; Lucena MI; Crespo J; Villa E; Arias-Loste MT; Iruzubieta P; de Las Heras J; Lopitz-Otsoa F; Simon J; Fern.ndez-Tussy P; Zubiete-Franco I; Barbier-Torres L; Fern.ndez-Ramos D; L.pez de Davalillo S; Guti.rrez-de-Juan V. A morphological method for ammonia detection in liver.PLoS One (Q1: 15 of 64). 12 – 3, pp. e0173914 – e0173914. PUBLIC LIBRARY SCIENCE, 2017. ISSN 1932-6203 DOI: 10.1371/journal.pone.0173914
15 Nicoletti P; Aithal GP; Bjornsson ES; Andrade RJ; Sawle A; Arrese M; Barnhart HX; Bondon-Guitton E; Hayashi PH; Bessone F; Carvajal A; Cascorbi I; Cirulli ET; Chalasani N; Conforti A; Coulthard SA; Daly MJ; Day CP; Dillon JF; Fontana RJ; Grove JI; Hallberg P; Hern.ndez N; Ib..ez L; Kullak-Ublick GA; Laitinen T; Larrey D; Lucena MI; Maitland-van; Martin JH; Molokhia M; Pirmohamed M; Powell EE; Qin S; Serrano J; Stephens C; Stolz A; Wadelius M; Watkins PB; Floratos A; Shen Y; Nelson MR; Urban TJ; Daly AK. Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study. Gastroenterology (D1, 1 of 80). 152 – 5, pp. 915 – 917. W B SAUNDERS CO-ELSEVIER INC, 2017. ISSN 0016-5085 DOI: 10.1053/j.gastro.2016.12.016
16 MARIA MIKUS; KIMI DROBIN; MARCUS GRY; JULIE BACHMANN; JOHAN LINDBERG; GETNET YIMER; ELENI AKLILLU; EYASU MAKONNEN; GETACHEW ADERAYE; JAMES ROACH; IAN FEAR; CAROLINE KAMPF; JENS G.PFERT; HUGO PERAZZO; THIERRY POYNARD; STEPHENS C; ANDRADE RJ.; LUCENA MI; NADIR ABER; MATHIAS UHL.N; PAUL B WATKINS; JOCHEN M SCHWENK; INA SCHUPPE-KOISTINEN. Elevated levels of circulating CDH5 and FABP1 in human drug-induced liver injury. Liver International (Q1: 16 of 80). 37 – 1, pp. 132 – 140. WILEY-BLACKWELL, 2017. ISSN 1478-3223 DOI: 10.1111/liv.13174
17 Barbier-Torres L; Iruzubieta P; Fern.ndez-Ramos D; Delgado TC; Taibo D; Guiti.rrez-de-Juan V; Varela-Rey M; Azkargorta M; Navasa N; Fern.ndez-Tussy P; Zubiete-Franco I; Simon J; Lopitz-Otsoa F; Lachiondo-Ortega S; Crespo J; Masson S; McCain MV; Villa E; Reeves H; Elortza F; Lucena MI; Hern.ndez-Alvarez M; Zorzano A; Andrade RJ; Lu SC; Mato JM; Anguita J; Rinc.n M; Mart.nez-Chantar ML.. The mitochondrial negative regulator MCJ is a therapeutic target for acetaminophen-induced liver injury. Nature Communications (D1: 3 of 64). 8 – 1, pp. 2068 – 2079. NATURE PUBLISHING GROUP, 2017. ISSN 2041-1723 DOI: 10.1038/s41467-017-01970-x
18 CAMILLA STEPHENS; AGUSTIN CASTIELLA; EVA M GOMEZ-MORENO; PEDRO OTAZUA; MIGUEL.NGEL L.PEZ-NEVOT; EVA ZAPATA; AIDA ORTEGA-ALONSO; FRANCISCO RUIZ-CABELLO; INMACULADA MEDINAC.LIZ; MERCEDES ROBLES-D.AZ; GERMAN SORIANO; EVA ROMAN; HACIBE HALLAL; JOS. M MORENO-PLANAS; MARTIN PRIETO; RA.L J ANDRADE; M ISABEL LUCENA. Autoantibody presentation in druginduced liver injury and idiopathic autoimmune hepatitis: the influence of HLA alleles. Pharmacogenetics and Genomics (Q2: 116/271). 26 – 9, pp. 414 – 422. LIPPINCOTT WILLIAMS & WILKINS, 2016. ISSN 1744-6872 DOI: 10.1097/FPC.0000000000000230
19 Inmaculada Medina-Caliz; MERCEDES ROBLES-DIAZ; BEATRIZ GARCIA-MU.OZ; CAMILLA STEPHENS; AIDA ORTEGA-ALONSO; MIREN GARCIA-CORTES; ANDRES GONZALEZ-JIMENEZ; JUDITH A SANABRIACABRERA; INMACULADA MORENO; M CARMEN FERNANDEZ; MANUEL ROMERO-GOMEZ; JOSE M NAVARRO; ANA M BARRIOCANAL; EVA MONTANE; HACIBE HALLAL; SONIA BLANCO; GERMAN SORIANO; EVA M ROMAN; ELENA GOMEZ-DOMINGUEZ; AGUSTIN CASTIELLA; EVA M ZAPATA; MIGUEL JIMENEZ-PEREZ; JOSE M MORENO; ANA ALDEA-PERONA; MANUEL HERNANDEZ- GUERRA; MARTIN PRIETO; MIGUEL E ZOUBEK; NEIL KAPLOWITZ; M ISABEL LUCENA; RAUL J ANDRADE. Definition and risk factors for chronicity following acute idiosyncratic drug-induced liver injury. Journal of Hepatology (D1 : 3 of 84). 65 – 3, pp. 532 – 542. (Position 29 of 30, corresponding author), 2016. ISSN 0168-8278 DOI: 10.1016/j.jhep.2016.05.003
20 P.r Hallberg; Niclas Eriksson; Luisa Iba.ez; Emmanuelle Bondon-Guitton; Reinhold Kreutz; Alfonso Carvajal; M Isabel Lucena; Esther Sancho Ponce; Mariam Molokhia; Javier Martin; Tomas Axelsson; Qun-Ying Yue; Patrik K E Magnusson; Mia Wadelius. Genetic variants associated with antithyroid drug-induced agranulocytosis: a genome-wide association study in a European population.Lancet Diabetes & Endocrinology (D1: 1/138). 4 – 6, pp. 507 – 516. (Position 7 of 14), 2016. ISSN 2213-8587 DOI: 10.1016/S2213-8587(16)00113-3
21 Robles-Diaz, M; GONZ.LEZ-JIM.NEZ, ANDR.S; MEDINA-C.LIZ, INMACULADA; STEPHENS, CAMILLA; GARC.A-CORT.S, MIREN; GARC.A-MU.OZ, BEATRIZ; ORTEGA-ALONSO, AIDA; BLANCO-REINA, ENCARNACI.N; GONZ.LEZ-GRANDE, ROC.O; JIM.NEZ-P.REZ, MIGUEL; REND.N, PALOMA; NAVARRO, JOSE MARIA; GINES, PERE; PRIETO, MARTIN; GARC.A-ELIZ, MARIA; BESSONE, FERNANDO; BRAHM, JAVIER R.; PARAN., RAYMUNDO; LUCENA, M.ISABEL; ANDRADE, RA.L. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Alimentary Pharmacology & Therapeutics (D1: 10/267 CORRESPONDING AUTHOR). 41 – 1, pp. 116 – 125. WILEY, 2015. ISSN 0269-2813 DOI: 10.1111/apt.13023
22 M. ROBLES-DIAZ; I. MEDINA-CALIZ; M.I. LUCENA; R.J. ANDRADE. Editorial: Showing due DILIgence – the lessons from anabolic steroids; authors’reply. Alimentary Pharmacology & Therapeutics. 41 – 3, pp. 324 – 324. WILEYBLACKWELL, 2015. Disponible en Internet en: <http://onlinelibrary.wiley.com/doi/10.1111/apt.13059/pdf>. ISSN 1365- 2036
EDITORIAL DE LA PUBLICACI.N SIGUIENTE: ROBLES-DIAZ, MERCEDES; GONZ.LEZJIM.NEZ, ANDR.S; MEDINA-C.LIZ, INMACULADA; STEPHENS, CAMILLA; GARC.A-CORT.S, MIREN; GARC.AMU.OZ, BEATRIZ; ORTEGA-ALONSO, AIDA; BLANCO-REINA, ENCARNACI.N; GONZ.LEZ-GRANDE, ROC.O; JIM.NEZ-P.REZ, MIGUEL; REND.N, PALOMA; NAVARRO, JOSE MARIA; GINES, PERE; PRIETO, MARTIN; GARC.A-ELIZ, MARIA; BESSONE, FERNANDO; BRAHM, JAVIER R; PARAN., RAYMUNDO; LUCENA, M.ISABEL; ANDRADE, RA.L. Distinct phenotype of hepatotoxicity associated with illicit use of anabolic androgenic steroids. Alimentary Pharmacology & Therapeutics 2015; 41(1):116-25 doi:10.1111/apt.13023 IF 2013: 5.478 (D1).
23 MIGUEL F. CARRASCOSA; JOS. R. SALCINES-CAVIEDES; M. ISABEL LUCENA; RAUL J. ANDRADE. Letter to the Editors. Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?. Journal of Hepatology (D1: 5/79). 62 – 3, pp. 751 – 752. ELSEVIER SCIENCE BV, 2015. ISSN 0168- 8278 DOI: 10.1016/j.jhep.2014.11.019
24 Chen M; SUZUKI A; BORLAK J; ANDRADE RJ; LUCENA MI. REVIEW. Drug-Induced liver injury: interactions between drug properties and host factors. Journal of Hepatology (D1: 5 of 79). 63 – 2, pp. 503 – 514. (Position 5 of 5, senior), 2015. ISSN 0168-8278 DOI: 10.1016/j.jhep.2015.04.016
25 MIGUEL F. CARRASCOSA; JOS. R. SALCINES-CAVIEDES; M. ISABEL LUCENA; RAUL J. ANDRADE. Acute liver failure following atorvastatin dose escalation: Is there a threshold dose for idiosyncratic hepatotoxicity?. Journal of Hepatology. Elsevier, 2014. ISSN 0168-8278
26 Arie Regev. Editorial: Drug-Induced Liver Injury: Morbidity, Mortality, and Hy’s Law. Gastroenterology. 147 – 1, pp. 20 – 24. W B SAUNDERS CO-ELSEVIER INC, 2014. Disponible en Internet en <http://www.sciencedirect.com/science/article/pii/S0016508514006751>. ISSN 0016-5085
27 PERDICES EV; MEDINA-C.LIZ I.; HERNANDO S.; ORTEGA A.; MART.N-OCA.A F.; NAVARRO JM; PEL.EZ G.; CASTIELLA A.; ZAPATA EM; HALLAL H.; ROMERO-G.MEZ M.; GONZ.LEZ-JIM.NEZ A.; ROBLES-D.AZ M.; LUCENA MI; ANDRADE RJ. Hepatotoxicity associated with statin use: Analysis of the cases included in the Spanish Hepatotoxicity Registry.Revista Espa.ola de Enfermedades Digestivas. 106 – 4, pp. 246 – 254. ARAN Ediciones S.A., 2014. ISSN 1130-0108
28 Robles-Diaz M.; M ISABEL LUCENA; NEIL KAPLOWITZ; CAMILLA STEPHENS; INMACULADA MEDINA-C.LIZ; ANDR.S GONZ.LEZ-JIM.NEZ; EUGENIA ULZURRUN; ANA F GONZ.LEZ; M CARMEN FERN.NDEZ; MANUEL ROMERO-G.MEZ; MIGUEL JIM.NEZ-P.REZ; MIGUEL BRUGUERA; MART.N PRIETO; FERNANDO BESSONE; NELIA HERN.NDEZ; MARCO ARRESE; RA.L J ANDRADE. Use of HyÅLs Law and a New Composite Algorithm to Predict Acute Liver Failure in Patients with Drug-induced Liver Injury.Gastroenterology (D1: 1 of 76). 147, pp. 109 – 118. (Position 2 of 17, corresponding author, accompanying editorial), 2014. ISSN 0016-5085
29 CAMILLA STEPHENS; MIGUEL-.NGEL L.PEZ NEVOT; FRANCISCO RUIZ CABELLO; EUGENIA ULZURRUN; GERM.N SORIANO; MANUEL ROMERO G.MEZ; ANTONIA MORENO CASARES; M. ISABEL LUCENA; RA.L J. ANDRADE. HLA Alleles Influence the Clinical Signature of Amoxicillin-Clavulanate Hepatotoxicity. PLoS One. (Q1: 9 of 57). 8 – 7, pp. e68111 – e68111. (Posicion 8 de 9), 2013. ISSN 1932-6203
31 GP AITHAL; PB WATKINS; RJ ANDRADE; D LARREY; M MOLOKHIA; H TAKIKAWA; CM HUNT; RA WILKE; M AVIGAN; N KAPLOWITZ; E BJORNSSON; AK DALY. Case definition and phenotype standardization in druginduced liver injury. Clin Pharmacol Ther.89, pp. 806 – 815. 2011.
32 M GARC.A-CORT.S; C STEPHENS; MI LUCENA; A FERN.NDEZ-CASTA.ER; RJ ANDRADE. Causality assessment methods in Drug Induced Liver Injury. Journal of Hepatology. 55 – (3), pp. 683 – 691. ELSEVIER SCIENCE BV, 2011. ISSN 0168-8278 DOI: 10.1016/j.jhep.2011.02.007
33 Christina Weiler-Normann; Christoph Schramm. Drug induced liver injury and its relationship to autoimmune hepatitis. Journal of Hepatology. 55, pp. 747 – 749. ELSEVIER SCIENCE BV, 2011. ISSN 0168-8278
34 MI LUCENA; N KAPLOWITZ; H HALLAL; A CASTIELLA; M GARCIA-BENGOECHEA; P OTAZUA; M
BERENGUER; M FERN.NDEZ; R PLANAS; RJ ANDRADE. Recurrent Drug-Induced Liver Injury with different drugs.
Analysis of nine cases in the Spanish DILI Registry. J Hepatology. 55 – (4), pp. 820 – 827. ELSEVIER SCIENCE BV,
2011.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
Fuente de impacto: WOS (JCR) Categoría: D1
Índice de impacto: 10.401 Revista dentro del 25%: Si
Posición de publicación: 5
Fuente de citas: SCOPUS Citas: 21
Resultados relevantes: AUTOR DE CORRESPONDENCIA Editorial del trabajo: Recurrent drug-induced liver injury
(DILI) with different drugs in the Spanish Registry: the dilemma of the relationship to autoimmune hepatitis. J
Hepatology 2011; 55(4): 820-7 Drug induced liver injury and its relationship to autoimmune hepatitis Christina Weiler-
Normann, Christoph Schramm Journal of Hepatology 2011; 55: 747–749 IF 2013: 10.401 (D1)
Publicación relevante: Si
35 MI LUCENA; MARIAM MOLOKHIA; YUFENG SHEN; THOMAS J. URBAN; GURUPRASAD P. AITHAL; RA.L J ANDRADE; CHRIS P. DAY; FRANCISCO RUIZ-CABELLO; PETER T. DONALDSON; CAMILLA STEPHENS; MUNIR PIRMOHAMED; MANUEL ROMERO-GOMEZ; JOSE MARIA NAVARRO; ROBERT J. FONTANA; MICHAEL MILLER; MAX GROOM; EMMANUELLE BONDON-GUITTON; ANITA CONFORTI; BRUNO STRICKER; ALFONSO CARVAJAL; LUISA IBANEZ; QUN-YING YUE; MICHEL EICHELBAUM; ARIS FLORATOS; ITSIK PEER; MARK J. DALY; DAVID B GOLDSTEIN; JOHN F DILLON; MATTHEW R NELSON; PAUL B. WATKINS; ANN K. DALY; AND SPANISH DILI REGISTRY. Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and class II alleles. Gastroenterology. 141 – 1, pp. 338 – 347. 2011.
36 A SUZUKI; EM BRUNT; DE KLEINER; R MIQUEL; TC SMYRK; RJ ANDRADE; MI LUCENA; A CASTIELLA; K LINDOR; E BJ.RNSSON. The use of liver biopsy evaluation in discrimination of idiopathic autoimmune hepatitis vs. Drug-Induced Liver Injury.Hepatology. 54 – 3, pp. 931 – 939. 2011.
37 SUZUKI AYAKO; RAUL J ANDRADE; EINAR BJORNSSON; MI LUCENA; M LEE WILLIAM; NANCY A YUEN; CHRISTINE M HUNT; JAMES W FRESTON. Drugs Associated with Hepatotoxicity and their Reporting Frequency of Liver Adverse Events in VigiBase: Unified List Based on International Collaborative Work. Drug Saf. 33, pp. 503 – 522. 2010.
38 MI LUCENA; ELENA GARC.A-MART.N; RA.L J. ANDRADE; CARMEN MARTINEZ; CAMILLA STEPHENS; JOHN RUIZ; EUGENIA ULZURRUN; M. CARMEN FERNANDEZ; MANUEL ROMERO-GOMEZ; AUGUSTIN CASTIELLA; RAMON PLANAS; JOS. ANTONIO DUR.N; ANA MELC.N DE DIOS; CARLOS GUARNER; GERMAN SORIANO; YOLANDA BORRAZ; JOS. A. G.. AGUNDEZ. Mitochondrial Superoxide Dismutase and Glutathione Peroxidase in Idiosyncratic Drug-Induced Liver Injury. Hepatology. 52, pp. 303 – 312. 2010.
39 FONTANA RJ; SEEFF LB; ANDRADE RJ; BJ.RNSSON E; DAY CP; SERRANO J; HOOFNAGLE JH. Standardization of Nomenclature and Causality Assessment in Drug- Induced Liver Injury: Summary of a Clinical Research Workshop.Hepatology. 2010. DOI: 10.1002/hep.23696
40 RJ ANDRADE; M ROBLES M.; E ULZURRUN; MI LUCENA. Drug-Induced Liver Injury: Insights from genetic studies. Pharmacogenomics. 10 – (9), pp. 1467 – 1487. 2009.
41 RJ ANDRADE; JOS. A.G. AG.NDEZ; MI. LUCENA; CARMEN MART.NEZ; RAQUEL CUETO; ELENA GARC.A-MART.N.. Pharmacogenomics in Drug Induced Liver Injury. Current Drug Metabolism 2009. 10, pp. 956 – 970. 2009.
42 MI LUCENA; RJ ANDRADE; N KAPLOWITZ; M GARC.A-CORTES; MC FERN.NDEZ; M ROMERO-GOMEZ; M BRUGUERA; HALLAL HACIBE; M ROBLES-DIAZ; JF RODRIGUEZ-GONZ.LEZ; JM NAVARRO; J SALMERON; P MARTINEZ-ODRIOZOLA; R P.REZ-ALVAREZ; R HIDALGO; BEHALF OF THE SPANISH GROUP FOR THE STUDY OF DRUG- (GEHAM). Phenotypic characterization of idiosyncratic drug-induced liver injury: The influence of age and gender. Hepatology. 49, pp. 2001 – 2009. 2009.
43 K PACHKORIA; MI LUCENA; E CRESPO; F RUIZ-CABELLO; S LOPEZ-ORTEGA; MC FERNANDEZ; M ROMERO-GOMEZ; JA DUR.N; Y BORRAZ; JM NAVARRO; RJ ANDRADE; (GEHAM). Analysis of IL-10 , IL-4 and TNF ? in Drug-induced Liver Injury (DILI) and its outcome. J Hepatol. 49, pp. 107 – 114. 2008.
44 M GARCIA-CORTES; MI LUCENA; K PACHKORIA; RJ ANDRADE. Evaluation of the Naranjo Adverse Drug Reactions Probability Scale in the Causality Assessment of Drug-Induced Liver Injury. Aliment Pharmacol Ther. 27, pp. 780 – 789. 2008.
45 MI LUCENA; RJ ANDRADE; CM MART.NEZ; E ULZURRUN; E GARC.A-MART.N; Y BORRAZ; C FERNANDEZ; M ROMERO-GOMEZ; A CASTIELLA; R PLANAS; J COSTA; S ANZOLA; JA AG.NDEZ. Glutathione-S-transferase M1 and T1 null genotypes as susceptibility factor for Idiosyncratic Drug-Induced Liver Injury. Hepatology. 48, pp. 588 – 596. 2008.
46 RJ ANDRADE; M ROBLES; A FERNANDEZ-CASTA.ER; S LOPEZ-ORTEGA; MC LOPEZ-VEGA; MI LUCENA. Assessment of drug-induced hepatotoxicity in clinical practice: a challenge for gastroenterologists. World J Gastroenterol. 13, pp. 329 – 340. 2007.
47 K PACHKORIA; MI LUCENA; F RUIZ-CABELLO; E CRESPO; MR CABELLO; ANDRADE RJ. Genetic polymorphisms of CYP2C9 and CYP2C19 are not related to drug-induced idiosyncratic liver injury (DILI). Br J Pharmacol. 150 – 6, pp. 808 – 815. 2007.
48 MI LUCENA; RAUL J ANDRADE; M CARMEN FERNANDEZ; KETEVAN PACHKORIA; GLORIA PELAEZ; JOSE A. DURAN; MACARENA VILLAR; LUIS RODRIGO; MANUEL ROMERO GOMEZ; RAMON PLANAS; JOAN COSTA; ANABEL BARRIOCANAL; CARLOS GUARNER; SONIA BLANCO; JOSE M NAVARRO; FERNANDO PONS; AGUSTIN CASTIELLA; GEHAM. Determinants of the clinical expresion of amoxicillin-clavulanate Hepatotoxicity: A prospective series from Spain. Hepatology. 44, pp. 850 – 856. 2006.
49 RJ ANDRADE; MI LUCENA; N KAPLOWITZ; M GARCIA MUNOZ; Y BORRAZ; K PACHKORIA; M GARCIA CORTES; MC FERNANDEZ; G PELAEZ; L RODRIGO; JA DURAN; J COSTA; R PLANAS; A BARRIOCANAL; C GUARNER; M ROMERO GOMEZ; T MU.OZ YAG.E; FJ SALMERON; R HIDALGO. Outcome of acute idiosyncratic drug induced liver injury: long-term follow-up in an Hepatotoxicity Registry. Hepatology. 44, pp. 1581 – 1588. 2006.
50 RJ ANDRADE; MI LUCENA; MC FERN.NDEZ; G PEL.EZ; K PACHKORIA; E GARC.A RUIZ; B GARC.A MU.OZ; R GONZ.LEZ GRANDE; A PIZARRO; JA DUR.N; M JIM.NEZ; L RODRIGO; M ROMERO GOMEZ; JM NAVARRO; R PLANAS; J COSTA; A SOLER; J JAVIER SALMER.N; R MART.N VIVALDI; OF LIVER DESEASE ON BEHALF OF THE SPANISH GROUP FOR THE STUDY. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish Registry over a 10-year period. Gastroenterology. 129 – (2), pp. 512 – 521. 2005.
51 RJ ANDRADE; MI LUCENA; A ALONSO; M GARC.A CORT.S; E GARC.A RUIZ; R BENITEZ; C FERN.NDEZ; G PELAEZ; M ROMERO; R CORPAS; JA DUR.N; M JIM.NEZ; L RODRIGO; F NOGUERAS; R MART.N VIVALDI; JM NAVARRO; J SALMER.N; F S.NCHEZ DE LA CUESTA; R HIDALGO. HLA class II genotype influences the type of liver injury in drug-induced idiosyncratic liver disease. Hepatology. 39 – (6), pp. 1603 – 1612. 2004.
52 MI LUCENA; R CAMARGO; RJ ANDRADE; JC PEREZ SANCHEZ; F. SANCHEZ DE LA CUESTA. Comparison of two clinical scales for causality assessment in hepatotoxicity. Hepatology. 33, pp. 123 – 130. WILEY-BLACKWELL, 2001.
53 DANIEL E. DI ZEO-SANCHEZ; PABLO SANCHEZ-NU.EZ; CAMILLA STEPHENS; M. ISABEL LUCENA. Characterizing Highly Cited Papers in Mass Cytometry through H-Classics.Biology-Basel (Q1: 19/93). MDPI, 2021. ISSN 2079-7737 DOI: 10.3390/biology10020104
54 MIGUEL EUGENIO ZOUBEK; JOS. PINAZO-BANDERA; AIDA ORTEGA-ALONSO; NELIA HERN.NDEZ; JAVIER CRESPO; FERNANDO CONTRERAS; INMACULADA MEDINA-C.LIZ; JUDITH SANABRIA-CABRERA; ROC.O SANJUAN-JIM.NEZ; ANDR.S GONZ.LEZ-JIM.NEZ; MIREN GARC.A-CORT.S; M ISABEL LUCENA; RA.L J ANDRADE; AND MERCEDES ROBLES-D.AZ.. Liver injury after methylprednisolone pulses: A disputable cause of hepatotoxicity. A case series and literature review.United European Gastroenterology Journal (Q2: 39/88). 7 – 6, pp. 825 – 837. SAGE PUBLICATIONS INC, 2019. ISSN 2050-6406 DOI: 10.1177/2050640619840147
55 ZOUBEK ME; WOITOK MM; SYDOR S; NELSON LJ; BECHMANN LP; LUCENA MI; ANDRADE RJ; BAST A; KOEK GH; TRAUTWEIN C; CUBERO FJ.. Protective role of c-Jun N-terminal kinase-2 (JNK2) in ibuprofeninduced acute liver injury.Journal of Pathology (D1: 6/78). 247 – 1, pp. 110 – 122. WILEY, 2019. ISSN 0022-3417 DOI: 10.1002/path.5174
56 GONZALEZ-JIMENEZ A; MCEUEN K; CHEN M; SUZUKI A; ROBLES-DIAZ M; MEDINA-CALIZ I; BESSONE F; HERNANDEZ N; ARRESE M; PARANA R; LUCENA MI; STEPHENS C; ANDRADE RJ.. The influence of drug properties and host factors on delayed onset of symptoms in Drug-Induced Liver Injury.Liver international (Q1: 19/88; CORRESPONDING AUTHOR). 39 – 2, pp. 401 – 410. WILEY, 2019. ISSN 1478-3223 DOI: 10.1111/liv.13952
57 Andrade RJ; Medina-Caliz I; Gonzalez-Jimenez A; Garcia-Cortes M; Lucena MI. Hepatic Damage by Natural Remedies. Seminars in Liver Disease (Q2: 32 of 84). 38 – 1, pp. 21 – 40. THIEME MEDICAL PUBL INC, 23/02/2018. ISSN 0272-8087 DOI: 10.1055/s-0038-1623518
58 Rivera P; Pastor A; Arrabal S; Decara J; Vargas A; S.nchez-Mar.n L; Pav.n FJ; Serrano A; Bautista D; Boronat A; de la Torre R; Baixeras E; Lucena MI; de Fonseca FR; Su.rez J. Acetaminophen-Induced Liver Injury Alters the Acyl Ethanolamine-Based Anti-Inflammatory Signaling System in Liver. Frontiers in Pharmacology (Q1, 48 of 261). 8, pp. 705 – 705. FRONTIERS MEDIA SA, 10/2017. ISSN 1663-9812 DOI: 10.3389/fphar.2017.00705
59 AIDA ORTEGA-ALONSO; CAMILLA STEPHENS; LUCENA MI; ANDRADE RJ. Case characterization, clinical features and risk factors in drug-induced liver injury. International Journal of Molecular Sciences. 17 – 5, pp. 714 – 714. (Posicion 3 de 4, co-senior), 2016. ISSN 1422-0067 DOI: 10.3390/ijms17050714
60 Stephens C; MORENO-CASARES M; L.PEZ-NEVOT M.; GARC.A-CORT.S M; MEDINA-C.LIZ I; HALLAL H; SORIANO G; ROMAN E.; RUIZ-CABELLO F; ROMERO-GOMEZ M; LUCENA MI; ANDRADE RJ. Killer Immunoglobulin-like receptor profiles are not associated with risk of amoxicillin-clavulanate-induced liver injury in Spanish patients. Frontiers in Pharmacology (Q1: 33 of 257). 7, pp. 280 – 280. (Position 11 of 12, corresponding author), 2016. ISSN 1663-9812 DOI: 10.3389/fphar.2016.00280
61 MENGUAL-MORENO E.; LIZARZ.BAL-GARC.A M; RUIZ-SOLER M; SILVA-SUAREZ N; ANDRADE-BELLIDO R; LUCENA-GONZ.LEZ M; BESSONE F.; HERN.NDEZ N.; S.NCHEZ A.; MEDINA-C.LIZ I.. Case reports of drug-induced liver injury in a reference hospital of Zulia state, Venezuela.Investigaci.n cl.nica. 56 – 1, pp. 3 – 12. INST INVESTIGACION CLINICA, 2015. ISSN 0535-5133 PMID: 25920181
62 Robles-Diaz M.; GARCIA-CORTES M.; MEDINA-CALIZ I.; GONZALEZ-JIMENEZ A; GONZALEZ-GRANDE R; NAVARRO JM; CASTIELLA A; ZAPATA EM; ROMERO-GOMEZ M; BLANCO S.; SORIANO G; HIDALGO R.; ORTEGA-TORRES M; CLAVIJO E; BERMUDEZ-RUIZ MP; LUCENA MI; ANDRADE RJ. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase as biomarkers in hepatotoxicity. Liver International (Q1: 13/79; CORRESPONDING AUTHOR). 35 – 11, pp. 2474 – 2482. WILEY, 2015. ISSN 1478-3223 DOI: 10.1111/liv.12834
63 Navarro VJ; Lucena MI.. Hepatotoxicity induced by herbal and dietary supplements.Semin Liver Dis. (Q1: 12 of 76). 34 – 2, pp. 172 – 193. (Position 2 of 2, senior), 2014. ISSN 0272-8087
64 STEPHENS C.; ANDRADE RJ; ISABEL LUCENA M.. Mechanisms of Drug-Induced Liver Injury.Curr Opin Allergy Clin Immunol.2014.
65 HERN.NDEZ N.; BESSONE F; S.NCHEZ A.; DI PACE M.; BRAHM J; ZAPATA R.; A CHIRINO R; D.VALOS M.; M.NDEZ-S.NCHEZ N.; ARRESE M.; SCHINONI M.; LUCENA MI; ANDRADE RJ.. Profile of idiosyncratic drug induced liver injury in Latin America. An analysis of published reports.Ann Hepatol.13 – 2, pp. 231 – 239. 2014.
66 Ulzurrun E.; STEPHENS C.; RUIZ-CABELLO F.; ROBLES-DIAZ M.; SAENZ-L.PEZ P.; HALLAL H.; SORIANO G.; ROMAN E.; FERNANDEZ MC; LUCENA MI.; ANDRADE RJ.. Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort.PLoS One. (Q1: 9 of 57). 9 – 4, pp. e94675 – e94675. (Position 11 of 12, corresponding author), 2014. ISSN 1932-6203 DOI: 10.1371/journal.pone.0094675
67 ROBLES-DIAZ M.; GARCIA-CORTES M.; MEDINA-CALIZ I.; GONZALEZ-JIMENEZ A.; GONZALEZ-GRANDE R.; NAVARRO JM; CASTIELLA A.; ZAPATA EM; ROMERO-GOMEZ M.; BLANCO S.; SORIANO G.; HIDALGO R.; ORTEGA-TORRES M.; CLAVIJO E.; BERMUDEZ-RUIZ MP; ANDRADE RJ; LUCENA MI. The value of serum aspartate aminotransferase and gamma-glutamyl transpetidase when calculating type of liver injury in hepatotoxicity.Liver International. 2014. ISSN 1478-3223
68 EUGENIA ULZURRUN; CAMILLA STEPHENS; ESPERANZA CRESPO; FRANCISCO RUIZ-CABELLO; JULIA RUIZ-NU.EZ; PABLO SAENZ-L.PEZ; INMACULADA MORENO-HERRERA; MERCEDES ROBLES-DIAZ; HACIBE HALLAL; JOS. MAR.A MORENO-PLANAS; MARIA ROSARIO CABELLO; M ISABEL LUCENA; RA.L J. ANDRADE. Role of chemical structures and the 1331T>C bile salt export pump polymorphism in idiosyncratic Drug- Induced Liver Injury.Liver International (Q1: 14 of 75). 33 – 9, pp. 1378 – 1385. (Posicion 12 de 13), 2013. T
69 FERNANDO BESSONE; NELIA HERNANDEZ; MILAGROS D.VALOS; RAIMUNDO PARAN.; M. ISABEL SCHINONI; MARIBEL LIZARZABAL; DAVID KERSHENOBICH; AURORA LOAEZA; MARCO ARRESE; RUBY ANN CHIRINO; NAHUM M.NDEZ S.NCHEZ; F. FAY; MIGUEL BRUGUERA; CAMILLA STEPHENS; M.ISABEL LUCENA; RAUL J. ANDRADE. Building a Spanish-Latin American network on drug induced liver injury: much to get from a joint collaborative initiative.Annals of Hepatology. 11 – 4, pp. 544 – 549. 2012.
70 GONZ.LEZ-CONTRERAS J.; VILLALOBOS G.MEZ JL; G.MEZ-S.NCHEZ AI; GARC.A-ALMEIDA JM; ENGUIX ARMANDA A.; RIUS D.AZ F.; LUCENA GONZ.LEZ MI.. Cholestasis induced by total parenteral nutrition: effects of the addition of Taurine (Tauramin.) on hepatic function parameters; possible synergistic action of structured lipids (SMOFlipid.).Nutr Hosp.27 – 6, pp. 1900 – 1907. 2012.
71 RAUL J. ANDRADE BELLIDO; M.ISABEL LUCENA. Editorial. Prescripci.n de f.rmacos en pacientes con hepatopat.a cr.nica: reglas para dosificaci.n y m.s all..Revista Espa.ola de Enfermedades Digestivas 2012; 104(4): 161-164. 104 – 4, pp. 161 – 164. 2012.
72 CAMILLA STEPHENS; M.ISABEL LUCENA; RAUL J. ANDRADE. Genetic variations in drug-induced liver injury (DILI): resolving the puzzle. FRONTIERS IN GENETICS. 3, pp. 253 – 253. 2012.
73 MF CARRASCOSA; JR Caviedes; M. ISABEL LUCENA; A. Cuadrado Lav.n. Syndrome of inappropriate antidiuresis in doxylamine overdose. BMJ Case Reports. 2012. Disponible en Internet en: <10.1136/bcr-2012-007428>.
74 JA AGUNDEZ; F. ABAD SANTOS; A. ALDEA; H. ALONSO NAVARRO; ML BERNAL; AM BOROBIA; E. Borr.s; M. CARBALLO; A. CARVAJAL; JD Garc.a Mu.iz; G. Gervasini; FJ Jim.nez Jim.nez; M.ISABEL LUCENA; C. Mart.nez; JA Sacrist.n; I. SALADO; B. Sinu.s; J. Vicente; E. Garc.a Mart.n. Toward a clinical practice guide in pharmacogenomics testing for functional polymorphisms of drug-metabolizing enzymes. Gene/drug pairs and barriers perceived in Spain. Frontiers in Genetics. 3 – Article 253, pp. 273 – 273. 2012.
75 JA Ag.ndez; J. DEL BARRIO; T. PADRO; CAMILLA STEPHENS; M. FARRE; RAUL J. ANDRADE; L. BADIMON; E. Garc.a Mart.n; G. Vilahur; M.ISABEL LUCENA. Trends in qualifying biomarkers in drug safety. Consensus of the 2011 meeting of the spanish society of clinical pharmacology.FRONTIERS IN PHARMACOLOGY. 3, pp. 2 – 2. 2012.
76 JA AG.NDEZ; MI LUCENA; C MART.NEZ; RJ ANDRADE; M BLANCA; P AYUSO; E GARC.A-MART.N. Assessment of nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Expert Opin Drug Metab Toxicol.7, pp. 817 – 828. 2011.
77 GLORIA MANSO; LAUREANO L.PEZ-RIVAS; M ESTHER SALGUEIRO; JOSE M DUQUE; FRANCISCO J JIMENO; RAUL J ANDRADE; MI LUCENA. Continuous reporting of new cases in Spain support the relationship between Herbalife? products and liver injury.Pharmacoepidemiology and Drug Safety. 20 – 10, pp. 1080 – 1087. 2011.
78 A CASTIELLA; MI LUCENA; EM ZAPATA; P OTAZUA; RJ ANDRADE. Drug-Induced Autoimmune-Like Hepatitis: A Diagnostic Challenge. Dig Dis Sci. 56 – 8, pp. 2501 – 2502. 2011.
79 M LOZANO-LANAGR.N; M ROBLES; MI LUCENA; RJ ANDRADE. Hepatotoxicity in 2011–advancing resolutely. Rev Esp Enferm Dig.103 – 9, pp. 472 – 479. 2011.
80 MI LUCENA; H COHEN; N HERN.NDEZ; F BESSONE; C DACOLL; C STEPHENS; Y BORRAZ; E ULZURRUN; M BRUGUERA; RJ. ANDRADE. Hepatotoxicity, a global problem with local features: toward the creation of a Pan-American Hepatotoxicity Network. Gastroenterol Hepatol.34 – (5), pp. 361 – 368. 2011.
81 R Cueto Galan; J. Ruiz N..ez; M.I. Lucena Gonz.lez. Farmacolog.a del condroit.n sulfato. Arthros. VIII (2), pp. 5 – 17. 2010.
82 JOSEP-E. BA.OS; MI LUCENA; E. SERES; FELIX BOSCH. Reflections on running training workshops for research ethics committee members in Spain between 2001 and 2008. Croatian Medical Journal. 51, pp. 552 – 559. 2010.
83 ELENA TOSCANO; JUDIT COTTA; MERCEDES ROBLES; MI LUCENA; RJ ANDRADE. Toxicidad hep.tica inducida por los nuevos f.rmacos inmunosupresores. Gastroenterol Hepatol. 33, pp. 54 – 65. 2010.
84 E ULZURRUN; C MART.NEZ; MI LUCENA; E GARC.A-MART.N; Y BORRAZ; MC FERN.NDEZ; M ROMERO-GOMEZ; A CASTIELLA; J COSTA; S ANZOLA; RJ ANDRADE; JA AG.NDEZ.. El doble genotipo nulo de Glutation S-Transferasa M1 y T1 aumenta la susceptibilidad a desarrollar toxicidad hep.tica inducida por f.rmacos (DILI). Actualidad en Farmacolog.a y Terap.utica. 7(2), pp. 148 – 150.. 2009.
85 MF CARRASCOSA; MI LUCENA; RJ ANDRADE; JR CAVIEDES; AC LAV.N; JC MONES; AP RIVERO; VB SERRANO. Fatal acute hepatitis after sequential treatment with levofloxacin, doxycycline, and naproxen in a patient presenting with acute Mycoplasma pneumoniae infection. Clin Ther.31 – (5), pp. 1014 – 1019. 2009.
86 MI LUCENA; C MART.NEZ; RJ ANDRADE; E GARC.A-MART.N; E ULZURRUN; J AG.NDEZ; (GEHAM). Glutathione S-transferase M1 and T1 null genotypes increase susceptibility to drug-induced liver injury. Reply Letter – Hepatology. 49, pp. 1777 – 1778. 2009.
87 RJ ANDRADE; M ROBLES; MI LUCENA. Rechallenge in drug-induced liver injury: The attractive hazard. Expert Opinion on Drug Safety. 8, pp. 709 – 714. 2009.
88 A FERNANDEZ-CASTA.ER; M GARCIA-CORTES; MI LUCENA; Y BORRAZ; G PELAEZ; J COSTA; S ANZOLA; J SALMERON; S AVILA; JA DURAN; A MALCON DE DIOS; M ROMERO-GOMEZ; A MADRAZO; T MU.OZ-YAG.E; RJ ANDRADE. An.lisis de las causas, caracter.sticas y consecuencias de la reexposici.n al f.rmaco o compuesto responsable de un episodio de hepatotoxicidad. Rev Esp Enferm Dig. 100 (Supp 5), pp. 278 – 284. 2008.
89 MI LUCENA; M GARC.A-CORT.S; R CUETO; JL L.PEZ-DUR.N; RJ ANDRADE. Assessment of drug-induced liver injury in clinical practice. Fundam Clin Pharmacol. 22, pp. 141 – 158. 2008.
90 RJ ANDRADE; S L.PEZ-ORTEGA; MC L.PEZ-VEGA; M ROBLES; MI LUCENA. Idiosyncratic drug hepatotoxicity: a 2008 update. Expert Opin Clin Pharmacol. 1, pp. 261 – 276. 2008.
91 M GARC.A-CORT.S; Y BORRAZ; MI LUCENA; G PELA.Z; J SALMER.N; M DIAGO; MC MARTINEZ SIERRA; JM NAVARRO; R PLANAS; MJ SORIA; M BRUGUERA; RJ ANDRADE. Liver injury induced by “natural remedies”: an analysis of cases submitted to the Spanish Liver Toxicity Registry.Rev Esp Enferm Dig. 100, pp. 688 – 695. 2008.
92 RJ ANDRADE; M ROBLES; N ORTIZ; MI LUCENA. Rechallenge in hepatotoxicity: proof of concept or therapeutic accident?. Rev Esp Enferm Dig. 100, pp. 255 – 258. 2008.
93 RJ ANDRADE; M ROBLES; N ORTIZ; MI LUCENA. Reexposici.n en hepatotoxicidad: .prueba de concepto o accidente terap.utico?. Rev Esp Enferm Dig. 100 (Supp 5), pp. 255 – 258. 2008.
94 R CUETO; P VALDIVIESO; MI LUCENA; C GARCIA ARIAS; RJ ANDRADE; P GONZ.LEZ SANTOS. Statins: Hepatic Disease and Hepatotoxicity Risk. Open Gastroenterol J. 2, pp. 18 – 23. 2008.
95 RJ ANDRADE; MC LOPEZ VERA; MI LUCENA. Drug-induced hepatotoxicity. Hepatology Rev. 4, pp. 14 – 23.2007.
96 RJ ANDRADE; M GARCIA CORTES; MI LUCENA; S L.PEZ ORTEGA; MC L.PEZ VEGA; A FERN.NDEZ CASTA.ER; M ROBLES. Hepatotoxicidad. Clin Gastroenterol Hepatol. 7(4), pp. 7 – 19. 2007.
97 RJ ANDRADE; MI LUCENA. Hepatotoxicidad: apuntes en el nuevo milenio. Clin Gastroenterol Hepatol. 7(4), pp. 7- 19. 2007.
98 K PACHKORIA; MI LUCENA; M MOLOKHIA; R CUETO; A CARVAJAL; RJ ANDRADE. Molecular and Genetic factors in drug-induced liver injury: a review. Current Drug Safety. 2, pp. 97 – 112. 2007.
99 E LOPEZ TORRES; I COBO; MI LUCENA. Olanzapine-associated neuroleptic malignant syndrome: A case report and favourable response to risperidone. Actas Esp Psiquiatr. 35, pp. 145 – 146. 2007.
100 CARMEN VERGE; MI LUCENA; ENRIQUE LOPEZ TORRES; M JOSE PUCHE GARCIA; ENRIQUE FRAGA; MANUEL ROMERO GOMEZ; RAUL J ANDRADE. Adverse hepatic reactions associated with calcium carbimide and disulfiram therapy. Is there still a role for these drugs?. World J Gastroenterol. 12, pp. 5078 – 5080. 2006.
101 M GARCIA CORTES; RJ ANDRADE; S LOPEZ ORTEGA; MC LOPEZ VEGA; A FERNANDEZ CASTA.ER; M ROBLES; MI LUCENA. Medicina natural y hepatotoxicidad. Rev And Pat DigesT. 29 (extraordinario), pp. 54 – 60. 2006.
102 MJ PUCHE GARC.A; E L.PEZ TORRES; C VERGE; JL L.PEZ DUR.N; R CUETO GAL.N; MI LUCENA. Medidas adoptadas en materia de farmacovigilancia durante el a.o 2005. Rev And Pat Digest. 29, pp. 143 – 146. 2006.
103 Mi Lucena; RJ Andrade; L Vicioso; FJ Gonz.lez; K Pachkoria; B Garc.a Mu.oz. Prolongued cholestasis after raloxifene and fenofibrate interaction. World J Gastroenterol. 12, pp. 5244 – 5246. 2006.
104 MJ PUCHE-GARCIA; C VERGE; E LOPEZ-TORRES; MI LUCENA. S.ndrome neurol.ptico maligno asociado a olanzapina. Actualidad en Farmacolog.a y Terap.utica. 4, pp. 114 – 117. 2006.
105 MJ PUCHE GARCIA; C VERGE GONZALEZ; E LOPEZ TORRES; MI LUCENA. Uso de vancomicina en un paciente de edad avanzada. Actualidad en Farmacolog.a y Terap.utica. 4, pp. 190 – 192. 2006.
106 RJ ANDRADE; FJ GONZ.LEZ; L V.ZQUEZ; A CILVETTI; R CAMARGO; M GARC.A CORT.S; JV MARTOS VANDUSSEN; P ROS.N; MI LUCENA. Vascular ophthalmologic side effects associated with antiviral therapy for chronic hepatitis C are related to circulating vascular endothelial growth factor levels. Antiv Ther. 11, pp. 491 – 498. 2006.
107 R CUETO; E L.PEZ TORRES; MJ PUCHE; C VERGE; C LOPEZ DURAN; MC FERNANDEZ; F SANCHEZ DE LA CUESTA; MI LUCENA. Bases farmacol.gicas de los inhibidores de la bomba de protones.Rev And Pat Dig. 28, pp. 2(s) – 10(s). 2005.
108 F L.PEZ GARC.A; J BORR.S; C VERD.; VR SALAZAR; JA RUIZ; J SALES; MI LUCENA; RJ ANDRADE. Cholestatic hepatitis associated with repaglinide. Diabetes Care. 28(3), pp. 752 – 753. 2005.
109 F Bosch; P Morales; MI Lucena; JE Ba.os. El reto de los cursos de formaci.n para miembros de Comit.s .ticos de Investigaci.n Cl.nica. Rev And Pat Digest. 28(1), pp. 14 – 20. 2005.
110 R Gonz.lez-Grande; RJ Andrade; JV Martos-Van Dussen; P Ros.n; B Garc.a-Mu.oz; MI Lucena. Hepatotoxicidad en la pr.ctica cl.nica. Rev And Pat Digest. 28, pp. 41 – 49. 2005.
111 R CAMARGO; RJ ANDRADE; MI LUCENA. Hepatotoxicidad por f.rmacos utilizados en el control de la obesidad y trastornos metab.licos relacionados. Rev Esp Obes. 4(1), pp. 317 – 323. 2005.
112 M Garc.a Cort.s; RJ Andrade; MI Lucena; R Gonz.lez-Grande; R Camargo; E Fern.ndez Bonilla; JV Martos; R Alc.ntara. Hepatotoxicidad secundaria a f.rmacos de uso com.n. Gastroenterol Hepatol. 28(8), pp. 461 – 472. 2005.
113 MI LUCENA; RJ ANDRADE. Incrementando la detecci.n de reacciones adversas hepatot.xicas en la pr.ctica cl.nica: un compromiso de calidad. Rev Esp Enferm Dig. 97(3), pp. 145 – 153. 2005.
114 P Morales; F Bosch; MI Lucena; JE Ba.os. Seminaris de formaci. per a membres de CEIC: una experi.ncia catalana estesa a la esta dEspanya. Ann Med (Barc). 88, pp. 127 – 131. 2005.
115 MI LUCENA; E L.PEZ TORRES; C VERGE; J ANDRADE RJSEOANE; MJ PUCHE; F S.NCHEZ DE LA CUESTA. The administration of N-acetylcisteine causes a decrease in prothrombin time in patients with paracetamol overdose but without evidence of liver impairment. Eur J Gastroent Hepat. 17(1), pp. 59 – 63. 2005.
116 RJ ANDRADE; MI LUCENA. Toxicidad por medicamentos: detecci.n y tratamiento. Gastroenterol Hepatol. 28(Supl1), pp. 1 – 11.. 2005.
117 R CAMARGO; MI LUCENA; R GONZALEZ GRANDE. Causality assessment in drug-induced hepatotoxicity. Expert Opin Drug Saf. 3(4), pp. 329 – 344. 2004.
118 C VERGE; E LOPEZ TORRES; I PEREZ FERNANDEZ; MI LUCENA. El efecto menos deseable del metamizol.Actualidad en Farmacolog.a y Terap.utica. 2, pp. 104 – 104. 2004.
119 C VERGE; E LOPEZ; MI LUCENA; MJ PUCHE; RJ ANDRADE. Es el tiempo de protrombina un par.metro .til para predecir la lesi.n hep.tica grave en pacientes con intoxicaci.n por paracetamol?. Rev And Pat Dig. 27, pp. 158 – 162.. 2004.
120 R GONZALEZ GRANDE; RJ ANDRADE; MI LUCENA GONZALEZ; R ALCANTARA BENITEZ. Farmacolog.a de la hepatopat.a cr.nica. Medicine. 9, pp. 521 – 527. 2004.
121 A RUIZ EXTREMADURA; MI LUCENA; P JARA; C ROBLES; E OCETE; J SALMERON. Hepatotoxicidad por f.rmacos en la infancia.Anales Pediatria. 60(suppl 4), pp. 184 – 194. 2004.
122 MI LUCENA; E L.PEZ TORRES; C VERGE; J SEOANE; RJ ANDRADE. Hepatotoxicity related to citalopram.Am J Pshychiat. 161, pp. 923 – 924. 2004.
123 M Garcia Cortes; MI Lucena; RJ Andrade; R Camargo; R Alcantara. Is the Naranjo probability scale accurate enough to ascertain causality in drug-induced hepatotoxicity?. Ann Pharmacother. 38(9), pp. 1540 – 1541. 2004.
124 E LOPEZ TORRES; C VERGE; MI LUCENA. Reexposici.n positiva a alopurinol con desenlace fatal. Actualidad en Farmacolog.a y Terap.utica. 2, pp. 105 – 105. 2004.
125 M LEVINE; N STAUNTON; C PRITCHARD; MI LUCENA. Reimbursement and market access barriers to achieving asthma control in practice.Eur Respir Rev. 13, Review n.92,, pp. 116 – 118.. 2004.
126 E LOPEZ TORRES; P DOBLAS; M BARBER; S MONIS; J SEOANE; C VERGE; MI LUCENA; JA
GONZALEZ CORREA; M ABEHESERA. Antiarritmicos en el embarazo. Clinica e investigaci.n en
Ginecolog.a y Obstetr.cia. 30, pp. 18 – 23. 2003.
127 MI LUCENA; A CARVAJAL; RJ ANDRADE; A. VELASCO. Antidepressant-induced hepatotoxicity. Exp
Opin Drug Saf. 2, pp. 249 – 262. 2003.
128 E LOPEZ TORRES; MI LUCENA. Casos farmacoterap.uticos: Complicaciones durante la
terap.utica de la diabetes mellitus. Actualidad en Farmacolog.a y Terap.utica. 1, pp. 84 – 85..
2003.
129 R CAMARGO; RJ ANDRADE; MI LUCENA; R ALCANTARA. Diagn.stico de hepatotoxicidad. Rev And
Patol Dig. 26, pp. 7 – 11. 2003.
130 MI LUCENA; FELIX BOSCH; JOSEP-E BA.OS. Diez a.os de Comit.s Eticos de Investigaci.n Cl.nica: los
riesgos de la complacencia.Med Clin (Barc). 120, pp. 257 – 260. 2003.
131 MI LUCENA; RJ ANDRADE; G TOGNONI; R HIDALGO; F. S.NCHEZ DE LA CUESTA. Drug use for nonhepatic associated conditions in patients with liver cirrhosis. Eur J Clin Pharmacol. 59, pp. 71 – 76. 2003.
132 RJ ANDRADE; MI LUCENA. Drug-induced hepatotoxicity. N Engl J Med. 349, pp. 1974 – 1976 (author’s reply). 2003.
133 RJ ANDRADE; MI LUCENA; R CAMARGO. Epidemiolog.a de la hepatitis t.xica. GH Continuada. 2, pp. 183 – 189. 2003.
134 C VERGE; MI LUCENA; E L.PEZ; J SEOANE; M J PUCHE; JM FRAILE; R ANDRADE; F S.NCHEZ DE LA CUESTA. Evaluaci.n cl.nica de los f.rmacos utilizados en el tratamiento y profilaxis de la cirrosis hep.tica. Rev And Patol Dig. 26, pp. 61 – 67.. 2003.
136 RJ ANDRADE; MI LUCENA; R. GONZALEZ. Hepatitis inducida por t.xicos. Formas cl.nicas agudas. Tratamiento.GH Continuada. 2, pp. 197 – 202.. 2003.
137 M GARC.A CORT.S; MI LUCENA; RJ ANDRADE; M ROMERO GOMEZ; MC FERNANDEZ. Lansoprazole-induced hepatic dysfunction. Ann Pharmacother. 37(11), pp. 1731 – 1731. 2003. Tipo de producción: Art.culo cient.fico Tipo de soporte:
138 F BOSCH; E GUARDIOLA; GRUPO DE TRABAJO DEL ESTEVE FOUNDATION WORKSHOP. Lista de comprobaci.n (checklist) abreviada para la evaluaci.n de art.culos de investigaci.n biom.dica b.sica. Med Clin (Barc). 121(6), pp. 228 – 230. 2003.
139 E GALLARDO CABALLERO; MI LUCENA; RJ ANDRADE; L RODRIGO; J P.REZ-MART.NEZ; E GARC.A RUIZ. Severe toxic hepatitis related to clormethiazole. J Hepatol. 39, pp. 1092 – 1093. 2003.
140 JE BA.OS; F BOSCH; I GALENDE; MI LUCENA. Training for optimal service in Research Ethics Committees: an experience in Spain. ESRA Rapporteur. 19-21, 2003.
141 E LOPEZ TORRES; P DOBLAS; M BARBER; I EGUILUZ; I AGUILERA; J HIJANO; MI LUCENA; JA GONZALEZ CORREA; J HERRERA; J LARRACOECHEA. Uso de cocaina durante el embarazo. Clinica e investigaci.n en Ginecolog.a y Obstetr.cia. 30, pp. 59 – 63. 2003.
142 RJ ANDRADE; MI LUCENA. Acute fulminant hepatitis after treatment with rabeprazole and terbinafine. Is rabeprazole the culprit?. Arch Intern Med. 162, pp. 360 – 361. 2002.
143 RJ ANDRADE; MI LUCENA; C FERNANDEZ; JL VEGA; M GARC.A CORT.S; M CASADO; E GUERRERO SANCHEZ; F. PULIDO FERNANDEZ. Cholestatic hepatitis related to use of irbesartan. A case report and a literature review of angiotensin II antagonists associated hepatotoxicity. Eur J Gastroen Hepat. 14, pp. 887 – 890. 2002.
144 RJ ANDRADE; MI LUCENA; M GARC.A CORT.S; E GARC.A RUIZ; E FERN.NDEZ BONILLA; L.
V.ZQUEZ. Chronic hepatitis C, ibuprofen and liver damage. Am J Gastroenterol. 97, pp. 1854 – 0855.
2002.
145 EM FERNANDEZ BONILLA; RJ ANDRADE BELLIDO; MI LUCENA; E FRANQUELO VILLALONGA.
Cirrosis hep.tica y toxicidad por f.rmacos.Rev And Pat Digest. 25, pp. 74 – 80.. 2002.
146 MI LUCENA; RJ ANDRADE; JP DE LA CRUZ; E BLANCO; M RODRIGUEZ MENDIZABAL; A
ANGUERA; F. SANCHEZ DE LA CUESTA. Effects of Silymarin MZ80 on Oxidative Stress in Patients
with Alcoholic Cirrhosis. Results of a Randomized, Double-Blind, Placebo-Controlled Clinical Trial. Int J
Clin Pharmacol Ther. 40, pp. 2 – 8. 2002.
147 E GARC.A RU.Z; RJ ANDRADE; MI LUCENA; R CAMARGO. Evaluaci.n de causalidad en el da.o
hep.tico inducido por f.rmacos. Rev And Patol Dig. 25, pp. 172 – 177.. 2002.
148 R CAMARGO; RJ ANDRADE; MI LUCENA; R ALC.NTARA; A. CARVAJAL. Hepatotoxicidad por
antidepresivos. Rev Esp Enferm Dig. 94, pp. 759 – 765. 2002.
149 RJ ANDRADE; MI LUCENA; M GARCIA CORT.S. Hepatotoxicidad por infusi.n de hierbas.
Gastroenterol Hepatol. 25, pp. 327 – 332. 2002.
150 E LOPEZ TORRES; MI LUCENA; RJ ANDRADE; E GARCIA RUIZ; MC FERNANDEZ; G PELAEZ; MJ SORIA DE LA CRUZ; A PIZARRO. Hepatotoxicidad por tetrabamato. Presentaci.n de 7 casos y revisi.n de la bibliograf.a.Gastroenterol Hepatol. 25, pp. 589 – 593.. 2002. 1a9904668551e345a94a72d6c41aacb9 102
151 GP CARVAJAL; D GARCIA; SA SANCHEZ; MA VELASCO; D RUEDA; MI LUCENA. Hepatotoxicity associated with the new antidepressants. J Clin Psychiatry. 63, pp. 135 – 137. 2002.
152 J W REIDENBERG; MI. LUCENA. Improving peer review: A guide for reviewers of biomedical
research. Clin Pharmacol Ther. 72, pp. 469 – 473. 2002.
153 MI LUCENA; RJ ANDRADE; G TOGNONI; R HIDALGO; F. S.NCHEZ DE LA CUESTA. Multicenter hospital study on prescribing patterns for prophylaxis and treatment of complications of cirrhosis. Eur J Clin Pharmacol. 58, pp. 435 – 440. 2002.
154 L RODRIGO; R DE FRANCISCO; JM PEREZ PARIENTE; M RODRIGUEZ; V CADAHIA; R TOJO; MI LUCENA; RJ. ANDRADE. Nimesulide-induced severe hemolytic anemia and acute liver failure leading to liver transplantation. Scand J Gastroenterol. 37, pp. 1341 – 1343. 2002.
155 MI LUCENA; RJ ANDRADE; E GARC.A RUIZ; M. MADURGA. Tetrabamato: un apunte sobre la relaci.n beneficio-riesgo. Med Clin. 118, pp. 477 – 477. 2002.
156 MA PEIR.; MI LUCENA; A RUIZ EXTREMERA; P JARA; J ROMERO GONZALEZ; RJ ANDRADE. Toxicidad hep.tica por f.rmacos en la edad pedi.trica. Donde estamos y hacia donde caminamos. Anales Pediatria. 56, pp. 434 – 442.. 2002.
157 RJ ANDRADE; MI LUCENA; M GARC.A CORT.S; R ALC.NTARA; E. FERNANDEZ. Amoxicilina.cido clavul.nico en pacientes con peritonitis bacteriana espont.nea. Gastroenterol Hepatol. 24, pp. 367 – 368. 2001. Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
158 RJ ANDRADE; J SALMERON; MI LUCENA; V BELLOT; R. CAMARGO. Benzylpenicillin-induced
prolonged cholestasis. Ann Pharmacother. 35, pp. 783 – 784. 2001.
159 AE PIZARRO; RJ ANDRADE; M GARC.A CORT.S; MI LUCENA; JM PEREZ MORENO; M PUERTAS;
H SANCHEZ MARTINEZ; JL MONTERO; JA DUR.N; M JIMENEZ; A RUIZ MONTERO; MJ SOTO
CONESA; L RODRIGO; R DE FRANCISCO; R ALC.NTARA; R. CAMARGO. Hepatitis aguda por ticlopidina, presentacion de 12 casos y revisi.n de la literatura.Rev Neurol. 33, pp. 1014 – 1020. 2001.
160 M GARC.A CORT.S; RJ ANDRADE; MI LUCENA; H S.NCHEZ MART.NEZ; MC FERN.NDEZ; T FERRER; R MART.N VIVALDI; G PEL.EZ; F SU.REZ; M ROMERO G.MEZ; JL MONTERO; E FRAGA; R CAMARGO; R ALC.NTARA; MA PIZARRO; E. GARC.A RUIZ. Hepatotoxicidad por flutamida: an.lisis de una serie y revisi.n de la literatura. Rev Esp Enf Dig. 93, pp. 423 – 427. 2001.
161 RJ ANDRADE; MI LUCENA; MC FERN.NDEZ; JL VEGA; R. CAMARGO. Hepatotoxicity in patients with cirrhosis, an often unrecognized problem: Lessons from a fatal case related with amoxicillin/clavulanic acid. Digest Dis Sci. 46, pp. 1416 – 1419. 2001.
162 L RODRIGO; M MORENO; S CALLEJA; V MATEOS; RJ ANDRADE; MI. LUCENA. Riluzoleinduced acute pancreatitis. Am J Gastroenterol. 96, pp. 2268 – 2269. 2001.
163 RJ ANDRADE; MI LUCENA; M GARCIA CORT.S. Utilidad de los registros de hepatotoxicidad por f.rmacos. Gastroenterol Hepatol. 24, pp. 250 – 255. 2001.
164 RJ ANDRADE; MI LUCENA. .Es inevitable la hepatotoxicidad inducida por f.rmacos?. Rev Esp Enf Dig.
93, pp. 48 – 53. 2001.
165 RJ ANDRADE; MI LUCENA; J AGUILAR; MD LAZO; R CAMARGO; P MORENO; MD GARCIA ESCA.O; A MARQUEZ; R ALCANTARA; G. ALCAIN. Chronic liver injury related with the use of bentazepam: An unusual instance of benzodiazepine hepatotoxicity. Digest Dis Sci. 45, pp. 1400 – 1404. 2000.
166 RJ ANDRADE; MI LUCENA; MC FERNANDEZ; M. GONZALEZ. Fatal Hepatitis associated with nimesulide. J Hepatol. 32, pp. 174 – 174. 2000.
167 RJ ANDRADE BELLIDO; MI LUCENA GONZALEZ; A GOMEZ OUTES; R. CAMARGO CAMERO. Indicaciones y precauciones del empleo de f.rmacos en pacientes con hepatopat.a cr.nica.Medicine. 8, pp. 655 – 659. 2000.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
168 MI LUCENA; IM SANTOS AMAYA; MJ GONZALEZ DE SUSO; M DE LA GANDARA; MR CABELLO; F SANCHEZ DE LA CUESTA. La receta m.dica y la publicidad sobre medicamentos. Rev Org Col Med. 68, pp. 28 – 31. 2000.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
169 MI LUCENA; RJ ANDRADE; L RODRIGO; J SALMERON; A ALVAREZ; MA LOPEZ GARRIDO; R CAMARGO; R ALCANTARA. Trovafloxacin-induced acute hepatitis. Clin Infect Dis. 30, pp. 400 – 401. 2000.
170 MI LUCENA; RJ ANDRADE; A GOMEZ OUTES; M RUBIO; MR. CABELLO. Acute liver failure after treatment with nefazodone. Dig Dis Sci. 44, pp. 2577 – 2579. 1999.
171 RJ ANDRADE; MI LUCENA; R MARTIN VIVALDI; MC FERNANDEZ; F NOGUERAS; G PELAEZ; A GOMEZ OUTES; MD GARCIA ESCA.O; V BELLOT; A HERV.S; F C.RDENAS; F BERMUDEZ; M ROMERO; J.SALMER.N. Acute liver injury associated with the use of ebrotidine, a new H2-receptor antagonist. J Hepatol. 31, pp. 641 – 646. 1999.
172 MI LUCENA; G TOGNONI; F. SANCHEZ DE LA CUESTA. Comites .ticos de investigaci.n cl.nica: nuevas funciones en un nuevo escenario. Med Clin. 112, pp. 785 – 790. 1999.
173 G CARRANQUE; MI LUCENA; F RIUS; F SANCHEZ DE LA CUESTA. Dolor postoperatorio en cirug.a general abdominal. Cir Esp. 65, pp. 473 – 479. 1999.
174 R CAMARGO; MI LUCENA; RJ ANDRADE. Epidemiolog.a actual de las hepatopat.as t.xicas. Rev Gastroenterol. 1, pp. 664 – 684. 1999.
175 RJ ANDRADE; MI LUCENA; MC FERNANDEZ; F SUAREZ; JL MONTERO; E FRAGA; F HIDALGO. Fulminant liver failure associated with flutamide therapy for hirsutism. Lancet. 353, pp. 983 – 983. 1999.
176 R CAMARGO; RJ ANDRADE; MI LUCENA. Hepatotoxicidad por f.rmacos. Rev And Pat Digest. 22, pp. 109 – 120. 1999.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
177 A VALLANO; C AGUILERA; JM ARNAU; J-E BA.OS; JR LAPORTE. Management of postoperative pain in abdominal surgery in Spain. A multicentre drug utilization study. Br J Clin Pharmacol. 47, pp. 667 – 673. 1999.
178 MI LUCENAWorking group on hepatotoxicity studies. Methods Find Exp Clin Pharmacol. 21, pp. 43 – 44. 1999.
179 RJ ANDRADE; MI LUCENA; JL VEGA; M TORRES; FJ SALMERON; V BELLOT; MD GARCIA ESCA.O; P.: MORENO. Acarbose-associated hepatotoxicity. Diabetes Care. 21, pp. 2029 – 2030. 1998.
180 RJ ANDRADE; MI LUCENA; G TOGNONI. Hepatolog.a cl.nica y farmacoepidemiolog.a: un enfoque multidisciplinar pendiente.Gastroenterol Hepatol. 21, pp. 449 – 451.. 1998.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
181 MI LUCENA; E BLANCO; MA CORRALES; M. BERTHIER. Interaction of fluoxetine and valproid acid. Am J Psychiat. 155, pp. 575 – 575. 1998.
182 RJ ANDRADE; MI LUCENA; F. SANTALLA. Losartan-induced hepatotoxicity. Ann Pharmacother. 32, pp. 1371. 1998.
183 MI LUCENA; RJ ANDRADE; H SANCHEZ MARTINEZ; A. GOMEZ OUTES. Norfloxacin-induced cholestatic hepatitis. Am J Gastroenterol. 93, pp. 2309 – 2311. 1998.
184 RJ ANDRADE; MI LUCENA; JM PREZ MORENO. Proyecto de registro de reacciones adversas hepatot.xicas en Andalucia: resultados preliminares.Rev And Pat Digest. 21, pp. 69 – 70. 1998.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
185 RJ ANDRADE; MI LUCENA; MD GARCIA ESCA.O; R. CAMARGO. Severe idiosyncratic acute hepatic injury caused by paracetamol. J Hepatol. 28, pp. 1078 – 1078. 1998.
186 M RODRIGUEZ MENDIZABAL; MI LUCENA; MR CABELLO; E BLANCO; B RODRIGUEZ LOPEZ; DE LA CUESTA F. SANCHEZ. Variations in blood levels of aminoglycosides related to in vitro anticoagulant usage. Ther Drug Monitor. 20, pp. 88 – 91. 1998.
187 RJ ANDRADE; MI LUCENA; F MELGAREJO. .Hepatotoxicidad por isoniacida o por paracetamol?.Gastroenterol Hepatol. 21, pp. 314 – 315. 1998.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
188 RJ ANDRADE; M DE LA MATA; MI LUCENA; F LOPEZ RUBIO; MA CORRALES. Hepatitis aguda grave por alopurinol en pacientes con hiperuricemia asintom.tica e insuficiencia renal.Revisi.n de la literatura y an.lisis de los factores de riesgo.Gastroenterol Hepatol. 20, pp. 353 – 356. 1997.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
189 RJ ANDRADE; MI LUCENA; MC FERNANDEZ; G. PELAEZ. Hepatotoxicidad por paracetamol a dosis terap.uticas. Med Clin. 109, pp. 317 – 318. 1997.
190 MI LUCENA; J ALMAGRO; RJ ANDRADE; R HIDALGO SANCHEZ; F. SANCHEZ DE LA CUESTA. Oralcfenoterol versus sustained-release theophylline in adult asmathics. Int J Clin Pharmacol Ther. 35, pp. 19 -c23. 1997.
191 MI LUCENA; RJ ANDRADE; E BLANCO; MR CABELLO; F. SANCHEZ DE LA CUESTA. Reflexiones sobre la ley de ensayos cl.nicos. Med Clin. 108, pp. 317 – 317. 1997.
192 JA GONZALEZ CORREA; JP De La CRUZ; MI LUCENA; F SANCHEZ DE LA CUESTA. Effect of cyclosporin A on platelet aggregation and thromboxane/prostacyclin balance in a model of extrahepatic cholestasis in the rat. Thrombosis Res. 81, pp. 367 – 381. 1996. 1a9904668551e345a94a72d6c41aacb9 107
193 M CABELLO; G TOGNONI; MI LUCENA; F. SANCHEZ DE LA CUESTA. Farmacolog.a Cl.nica en Atenci.n Primaria: un desafio necesario. Med Clin. 107, pp. 299 – 302. 1996.
194 RJ ANDRADE; MI LUCENA; M. RODRIGUEZ MENDIZABAL. Hepatic injury caused by acarbose. Ann Intern Med. 124, pp. 931 – 931. 1996.
195 MI LUCENA; RJ ANDRADE; M RODRIGUEZ MENDIZABAL; M CABELLO PORRAS; F SANCHEZ DE LA CUESTA. Selecci.n de medicamentos en el hospital. Un modelo de prestaciones referencial.An Med Intern. 13, pp. 505 – 510. 1996.
196 RJ ANDRADE; MI LUCENA; R ALCANTARA; F MELGAREJO; MR CABELLO; MD GARCIA ESCA.O; E BLANCO. Uso de f.rmacos en pacientes con enfermedades hep.ticas.Rev And Pat Digest. 19, pp. 165 – 171.. 1996.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
197 MI LUCENA; M MARQUEZ; JL VELASCO; RJ. ANDRADE. Acute renal failure due to ciprofloxacin in a patient with the adquired immunodeficiency sindrome. Arch Intern Med. 155, pp. 114 – 114. 1995.
198 MI LUCENA; RJ ANDRADE; MR CABELLO; R HIDALGO; JA GONZALEZ CORREA; F. SANCHEZ DE LA CUESTA. Aminoglycoside-associated nephrotoxicity in extrahepatic obstructive jaundice. J Hepatol. 22, pp. 189 – 196. 1995.
199 MI LUCENA; JM RUIZ; RJ ANDRADE; R HIDALGO; JA GONZALEZ CORREA; A GARCIA; F. SANCHEZ DE LA CUESTA. Impacto de la hospitalizaci.n sobre la prescripci.n de f.rmacos. Med Clin. 104, pp. 211 – 215. 1995.
200 RJ ANDRADE; MI. LUCENA. Interferon treatment of cirrhotic patients with chronic hepatitis C. Am J Gastroenterol. 90, pp. 678 – 679. 1995.
201 M. Isabel Lucena; Ra.l J. Andrade. Nefrotoxicidad por aminogluc.sidos e ictericia obstructiva. Medicina Cl.nica. 105, pp. 457 – 460. Elsevier, 1995. ISSN 0025-7753
202 RJ ANDRADE; MI LUCENA; R ALCANTARA; JM. FRAILE. Bentazepam-associated chronic liver disease. Lancet. 343, pp. 860 – 860. 1994.
203 RJ ANDRADE; MI LUCENA; R ALCANTARA; JM. FRAILE. Bentazepam-associated chronic liver disease. Lancet Reactions. 343, pp. 860 – 860. 1994.
204 RJ ANDRADE; MI LUCENA; R ALCANTARA; JM FRAILE. Bentazepam-associated chronic livervdisease. Reactions. 497 (16 April), pp. 5 – 5.. 1994.
205 MI LUCENA; RJ ANDRADE; JM FRAILE; R ALCANTARA; JA GONZALEZ CORREA; F. SANCHEZ DE LA CUESTA. Endogenous digoxin-like substance in severe liver failure. Int J Clin Pharmacol Ther (Toxicol). 32, pp. 567 – 569. 1994.
206 MI LUCENA; RJ ANDRADE; JM FRAILE; F. SANCHEZ DE LA CUESTA. Insuficiencia hep.tica y substancias immunoreactivas semejantes a la digoxina. Gastroenterol Hepatol. 17, pp. 499 – 500. 1994.
207 JA VALLES; A VALLANO; F TORRES; JM ARNAU; JR LAPORTE; MR CABELLO; JA GONZALEZ CORREA; MI. LUCENA. Multicentre Hospital drug utilization study of the prophylaxis of venous thromboembolism. Br J Clin Pharmacol. 37, pp. 255 – 259. 1994.
208 MI LUCENA GONZALEZ; RJ ANDRADE BELLIDO; MR CABELLO; F SANCHEZ DE LA CUESTA. Antibioterapia en geriatr.a. Ciencia M.dica. 2, pp. 36 – 42. 1993.
209 MI LUCENA GONZALEZ; JA GONZALEZ CORREA; MD GARCIA DOMINGUEZ; RJ ANDRADE BELLIDO; MR CABELLO PORRAS; F SANCHEZ DE LA CUESTA. An.lisis comparativo de la utilizaci.n de medicamentos en diferentes poblaciones ambulatorias de ancianos. Geriatrika. 9, pp. 185 – 194. 1993.
210 MI LUCENA GONZALEZ; JA GONZALEZ; MD GARCIA DOMINGUEZ; RJ ANDRADE BELLIDO; MR CABELLO PORRAS; F SANCHEZ DE LA CUESTA. An.lisis comparativo de la utilizaci.n de medicamentos en diferentes poblaciones ambulatorias de ancianos. Geriatrika (Ed. Argentina). 8, pp. 320 – 327.. 1993.
211 MI LUCENA GONZALEZ; RJ ANDRADE BELLIDO; MR CABELLO; F SANCHEZ DE LA CUESTA. Farmacolog.a y terap.utica. Antibioterapia en geriatr.a.Geriatrika (Ed. Argentina). 8, pp. 226 – 232. 1993.
212 MI LUCENA; RJ ANDRADE; MR CABELLO; E CLAVIJO; E QUEIPO. Imipenem/Cilastatin First report of hiccups: case report.Reactions. 437, pp. 8 – 8.. 1993.
213 MI LUCENA; RJ ANDRADE; MR CABELLO; E CLAVIJO; E. QUEIPO. Imipenem/cilastatin. First report of hiccups: case report. Clinical Abstracts/Current Therapeutic Problems. pp. 1459 – 1459. 1993.
214 RJ ANDRADE; MI LUCENA; JA GONZALEZ CORREA; C GARCIA-ARIAS; P. GONZALEZ SANTOS. Short term effects of various doses of cyclosporin A on plasma lipoproteins and its distribution in blood. Experimental study. Hum Exp Toxicol. pp. 141 – 146. 1993.
215 RJ ANDRADE; MI LUCENA; JA GONZALEZ CORREA; P GONZALEZ SANTOS. The effect of experimental bile duct ligation on distribution of cyclosporin A among plasma lipoproteins. Transplant Proc. 25, pp. 2972 – 2976. 1993.
216 MI LUCENA; RJ ANDRADE; M CABELLO; F SANCHEZ DE LA CUESTA. Antibioterapia en geriatria. Geriatrika. 8, pp. 173 – 179.. 1992.
217 MI LUCENA GONZALEZ; MD GARCIA DOMINGUEZ; RJ ANDRADE BELLIDO; R HIDALGO SANCHEZ; JM RAMIREZ TORRES; F. SANCHEZ DE LA CUESTA. An.lisis de las pautas de dosificaci.n de medicamentos en pacientes geri.tricos. Med Clin. 1992.
218 MI LUCENA GONZALEZ; RJ ANDRADE BELLIDO; M CABELLO PORRAS; F SANCHEZ DE LA CUESTA. Cefalosporinas: propiedades cl.nico-farmacol.gicas y criterios para su elecci.n. Geriatrika. 8, pp. 49 – 55. 1992. Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
219 RJ ANDRADE; MI LUCENA; P VALDIVIELSO; A LARA; G GARCIA-FERNANDEZ; P GONZALEZSANTOS. Ceftriaxona y coagulaci.n sanguinea en pacientes cirr.ticos. Rev Esp Enf Digest. pp. 294 – 296. 1992.
220 RJ ANDRADE; MI LUCENA. Derecho de replica al revisor. Med Clin. pp. 638 – 638. 1992.
221 MI LUCENA; MR CABELLO; MT GALVEZ; F SANCHEZ DE LA CUESTA. Drogas de abuso en orina de poblaci.n drogodependiente. Farm Hosp. 16, pp. 418 – 419. 1992.
222 MI LUCENA; R RODRIGUEZ RIVERA. Estudio multic.ntrico sobre el uso de medicamentos durante el embarazo en Espa.a (II). Los f.rmacos utilizados durante la gestaci.n. Med Clin. pp. 329 – 332. 1992.
223 MI LUCENA; R RODRIGUEZ RIVERA. Estudio multic.ntrico sobre el uso de medicamentos durante el embarazo en Espa.a (III). Los f.rmacos utilizados durante el primer trimestre de la gestaci.n. Med Clin. pp. 329 – 332. 1992. Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
224 MI LUCENA; R RODRIGUEZ RIVERA. Estudio multic.ntrico sobre el uso de medicamentos durante el embarazo en Espa.a.1. M.todos y caracter.sticas demogr.ficas de la poblaci.n estudiada. Med Clin. pp. 329 – 332. 1992. Tipo de producción: Art.culo cient.fico
225 RJ ANDRADE; MI LUCENA; C MEDINA; D LAZO; JA GONZALEZ CORREA; F SANCHEZ DE LA CUESTA. Evaluaci.n de la coagulaci.n sangu.nea en pacientes cirr.ticos en tratamiento con cefonicida. Rev Clin Esp. pp. 160 – 161. 1992.
226 E MARQUEZ; MI LUCENA; RJ ANDRADE; JA GONZALEZ-CORREA; E CLAVIJO; MD LAZO; DE LA CUESTA F. SANCHEZ. Evaluaci.n de la incidencia de nefrotoxicidad asociada al uso de aminogluc.sidos en pacientes con obstrucci.n biliar extrahep.tica. Rev Clin Esp. pp. 76 – 79. 1992.
227 MI LUCENA. Farmacocin.tica de la unidad materno-placentaria-fetal. Rev Farmacol Clin Exp. especial, pp. 73 – 78. 1992.
228 MI LUCENA; RJ ANDRADE; MR CABELLO; E CLAVIJO; E. QUEIPO. Imipenem cilastatin associated hiccoughs. The Annals of Pharmacotherapy. pp. 1459 – 1459. 1992.
229 MD GARCIA DOMINGUEZ; MI LUCENA GONZALEZ; JM RAMIREZ TORRES; RJ ANDRADE BELLIDO; JA GONZALEZ CORREA; F SANCHEZ DE LA CUESTA. Patr.n de utilizaci.n de medicamentos en una poblaci.n geri.trica ambulatoria. Rev Clin Esp. pp. 412 – 415. 1992.
230 MI LUCENA; R MARIN; F SANCHEZ DE LA CUESTA. Comparative study of the efficacy of dipyrone, diclofenac sodium and pethidine in acute renal colic. Eur J Clin Pharmacol. pp. 543 – 546. 1991.
231 MI LUCENA; R RODRIGUEZ RIVERA. Estudio multic.ntrico sobre el uso de medicamentos durante el embarazo en Espa.a (II). Los f.rmacos utilizados durante la gestaci.n. Med Clin. pp. 11 – 15. 1991.
232 MI LUCENA; R RODRIGUEZ RIVERA. Estudio multic.ntrico sobre el uso de medicamentos durante el embarazo en Espa.a (III). Los f.rmacos utilizados durante el primer trimestre de la gestaci.n. Med Clin. pp. 52 – 57. 1991. Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
233 MI LUCENA; JC RICO; MA TARILONTE; RJ ANDRADE; JA GONZALEZ CORREA; F SANCHEZ DE LA CUESTA. Conocimientos y actitudes de pacientes ambulatorios frente a algunos aspectos del tratamiento farmacol.gico. Rev Clin Esp. pp. 447 – 449. 1990.
234 MI LUCENA; R RODRIGUEZ RIVERA. Estudio multic.ntrico sobre el uso de medicamentos durante el embarazo en Espa.a.1. M.todos y caracter.sticas demogr.ficas de la poblaci.n estudiada. Med Clin. pp. 764 – 767. 1990. Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
235 MI LUCENA; RJ ANDRADE. Extrahepatic cholestasis as a distinc factor predisposing to gentamicin nephrotoxicity. Am J Med. pp. 698 – 699. 1990.
236 R ANDRADE; JA GONZALEZ CORREA; MI LUCENA; J IBA.EZ; D TORRES; F SANCHEZ DE LA CUESTA. Influencia de la obstrucci.n biliar experimental sobre la cin.tica y nefrotoxicidad de la gentamicina en la rata. Gastroenterol Hepatol. 13, pp. 99 – 104. 1990.
237 MI LUCENA; JA GONZALEZ-CORREA; R ANDRADE; J IBA.EZ; D TORRES; F SANCHEZ DE LA CUESTA. Enhanced gentamicin nephrotoxicity after experimental biliary obstruction in rats. Pharmacology Toxicology. pp. 352 – 356. 1989.
238 MI LUCENA GONZALEZ; RJ ANDRADE BELLIDO; F SANCHEZ DE LA CUESTA. Utilizaci.n de psicof.rmacos en geriatria. Medicina Geriatrica. 2, pp. 293 – 301. 1989.
239 MI LUCENA; J ALMAGRO; F RIUS; F SANCHEZ DE LA CUESTA. Bronchodilator effect and serum theophylline level after combined treatment with fenoterol and theophylline in reversible chronic airflow obstruction. Eur J Clin Pharmacol. pp. 669 – 671. 1988.
240 MI LUCENA GONZALEZ; J DE PABLO MOLINA; P SANCHEZ DE IBARGUEN. Consideraciones sobre terap.utica en geriatria. Rev Org Col Med. 18, pp. 1 – 5.. 1987.
241 MI LUCENA; A MORENO; MC FERNANDEZ; M GARCIA-MORILLAS; R.J. ANDRADE. Digitoxin elimination in healthy subjects taking ampicillin.Int J Clin Pharm Res. pp. 33 – 37. 1987.
242 A GARCIA RUIZ; F RIUS; MI LUCENA; A GOMEZ; F SANCHEZ DE LA CUESTA. Dise.o de un r.gimen de dosificaci.n inicial mediante un programa para ordenador personal. Farmacoterapia. 4, pp. 280 – 283.. 1987. Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista 1a9904668551e345a94a72d6c41aacb9 113
243 JM BAEYENS; MI LUCENA. Fichas farmacol.gico cl.nicas: Sisomicina y netilmicina, succinilcolina, sucralfato, sulfadiazina, sulfasalazina, sulfinpirazona, sulfisoxazol, sulindac, suramina, tamoxifen, teofilina, terbutalina, testosterona y metiltestosterona, tetraciclina y oxitetraciclina, tiabendazol, tiamina. Medicine. 84, pp. 1 – 8.. 1987.
244 MI LUCENA; JM BAEYENS. Fichas farmacol.gico cl.nicas: Ticarcilina. Timolol. Tiopental.Tioridacina. Tiroxina y Triyodotironina. Tobramicina. Tocainida. Tolbutamida. Tolmetin. Tranilcipromina y fenelcina. Trazodona. Triamcinalona. Triamtereno. Triazolam. Triafluoperacina. Trimetadiona.Medicine. 90, pp. 1 – 8.. 1987.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
245 MI LUCENA; JM BAEYENS. Fichas farmacol.gico cl.nicas: progesterona, hidroxiprogesterona y medroxiprogesterona. Prometacina. Propantelina. Propiltiouracilo. Propranolol. Prostaglandinas E2, F2. y metil-F2.. Protamina. Protriptilina. Quenodesoxicolico y ursodesoxicolico. Quinidina. Ranitidina. Reserpina. Rifampicina. Ritodrina. Salbutamol. Medicine. 78, pp. 1 – 8.. 1987.
246 MI LUCENA; JM BAEYENS. Fichas farmacol.gico-cl.nicas.:amrinona, auranofina, aztreonam, ciclosporina, cinoxacina y norfloxacina, danazol, enalapril, etidronato dis.dico, estreptoquinasa y uroquinasa, famotidina, gemfibrozil, metilfenidato, paracetamol, pirenzepina, praziquantel y somatostatina.Medicine. 98, pp. 1 – 8.. 1987.
247 JM BAEYENS; MI LUCENA. Fichas farmacol.gico-cl.nicas: Trioxsalen y metoxsalen, tubocurarina, valproato s.dico, vancomicina, vasopresina y an.logos, verapamil, vidarabina, viloxacina, vinblastina, vincristina, vitamina A, vitamina B12, vitamina C, vitamina D, warfarina y amoxapina. Medicine. 93, pp. 1 – 8.. 1987.
248 MI LUCENA; A MORENO; C GARCIA DEL RIO; MJ BOLA.OS; R ANDRADE. Haemodynamic and endocrine effects of digitoxin in healthy volunteers. Int J Clin Pharm Res. pp. 135 – 140. 1987.
249 A GARCIA; F MARTOS; A GOMEZ; JP CORTES; MI LUCENA; DE LA CUESTA F SANCHEZ. Consumo global de medicamentos en las comunidades aut.nomas del estado espa.ol durante los a.os 1975/83. Farmacoterapia. 3, pp. 52 – 55.. 1986.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
250 MI LUCENA; JM BAEYENS. Fichas farmacol.gico-cl.nicas: oro sales de, oxacepam, oxido nitroso, oxitocina, oxprenolol, pancuronio, penicilamina, penicilina G, pentazocina, pimozide y penfluridol, pindolol, piperacilina y mezlocilina, piperazina, pirazinamida, piridostigmina. Medicine. 68, pp. 1 – 8.. 1986.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
251 JM BAEYENS; MI LUCENA. Fichas farmacol.gico cl.nicas: isotretinoina y etretinato, ketamina, ketoconazol, labetalol, lactulosa, levodopa, lidocaina, litio, carbonato de lomustina (CCNU) y semustina, loperamida, loracepam, bromacepam, loxapina, manitol, maprotilina, mebendazol, meperidina. Medicine. 53, pp. 1 – 8.. 1986.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
252 MI LUCENA; JM BAEYENS. Fichas farmacol.gico-cl.nicas: meprobamato, mercaptopurina, metadona, metaproterenol, metildopa, metilergonovina y ergonovina, metimazol y carbimazol, metisergida, metoclopramida, metoprolol, metotrexato, metronidazol, mexiletina, mianserinna, miconazol, minoxidilo. Medicine. 59, pp. 1 – 8.. 1986.
253 JM BAEYENS; MI LUCENA. Fichas farmacol.gico-cl.nicas: mitramicina, morfina, moxalactam, .cidos nalid.xico y oxon.lico, naloxona, naproxen, neostigmina, niclosamida, nicot.nico, nifedipina, niridazol, nistatina, nitrofurantoina, nitroglicerina, nitroprusiato, nortriptilina. Medicine. 65, pp. 1 – 8.. 1986.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
254 JM BAEYENS; MI LUCENA. Fichas farmacol.gico-cl.nicas: piridoxina (B-6), pirimetamina, piroxicam, pirvinio pamoato de, polimmixinas B y E, politiazida-meticlotiazida y triclormetiazida, pralidoxima, prazosin, prednisona y prednisolona, primaquina, primidona, probenecid, probucol, procaina, procainamida, procarbazina. Medicine. 73, pp. 1 – 8.. 1986.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
255 F MARTOS; MI LUCENA; M POSTIGO; A GARCIA; JP CRUZ; A GOMEZ; f SANCHEZ DE LA CUESTA. F.rmacos antiarr.tmicos y receptores muscar.nicos cardiacos.Rev Farmacol Clin Exp. 2, pp. 111 – 115. 1986. Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
256 MI LUCENA; F MARTOS; A GOMEZ; A. GARRIDO. La Farmacolog.a Cl.nica: presente y perspectivas de futuro. Rev Org Col Med. 13, pp. 28 – 29. 1986.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
257 F MARTOS; MI LUCENA; E GIRALDO; A GARCIA; A GOMEZ; F SANCHEZ DE LA CUESTA. Union de quinidina a los receptores muscar.nicos cardiacos. Rev Farmacol Clin Exp. 4, pp. 287 – 293. 1986.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
258 F PADILLA; MI LUCENA; F MARTOS; A GOMEZ; F SANCHEZ DE LA CUESTA. Utilizaci.n de antibi.ticos en el medio extrahospitalario. Farmacoterapia. 3, pp. 283 – 286.. 1986.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
259 MI LUCENA; JM BAEYENS. Fichas farmacol.gico-cl.nicas: colestiramina y colestipol, cotrimoxazol, cromoglicato dis.dico, dacarbacina (DTCI), dantroleno, dapsona, demeclocilina y metacilina, desferrioxamina, dexametasona, dextranos 40, 70 y 75, dextrometorfano, dextropropoxifeno, diacepam, diazoxido, dibekacina, diclofenac. Medicine. 28, pp. 1 – 8.. 1985.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
260 JM BAEYENS; MI LUCENA. Fichas farmacol.gico-cl.nicas: dietilcarbamacina, dietilestilbestrol, difenhidramina, difenilhiantoina, difenoxilato, digitoxina, digoxina, diltiacem, dinitrato de isosorbide, dipiridamol, disopiramina, disulfiram, domperidone, dopamina, dobutamina, doxepinna, doxiciclina, minociclina. Medicine. 34, pp. 1 – 8.. 1985.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
261 MI LUCENA; JM BAEYENS. Fichas farmacol.gico-cl.nicas: eritromicina, escopolamina, espectinomicina, espironolactona, estreptomicina, etacr.nico .cido, etambutol, etinilestradiol, etomidato, etosuximida, fenfluramina, fenformina y metformina, fenilbutazona, fenilefrina, fenobarbital, fentolamina. Medicine. 40, pp. 1 – 8.. 1985.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
262 JM BAEYENS; MI LUCENA. Fichas farmacol.gico-cl.nicas: fisostigmina, fitonadiona, fludrocortisona, flufenacina, flunitracepam y nitracepam, fluorocitosina, fluorouracilo, f.lico .cido, fosfomicina, furosemida, gentamicina, glibenclamida y otras sulfonilureas de segunda generaci.n, glucagon, griseofulvina, guanetidina, haloperidol y droperidol. Medicine. 43, pp. 1 – 8.. 1985.
263 MI LUCENA; JM BAEYENS. Fichas farmacol.gico-cl.nicas: halotano, heparina, hidralacina, hidroclorotiacida y clorotiacida, hidrocortisona, hidroxidos de aluminio y magnesio, hierro sales de, I elemento y yoduros, ibuprofen, flurbiprofen, ketoprofen y fenoprofen, idoxuridina, imipramina y desmetilimipramina, indometacina, insulina,ipratopium, isoniacida,isoproterenol o isoprenalina. Medicine. 47 – 47, pp. 1 – 8.. 1985.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
264 GONZALEZ MI LUCENA. Informaci.n al paciente sobre medicamentos y su repercusi.n en el cumplimiento de la prescripci.n. Medicine. 40, pp. 217 – 226.. 1985.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
265 MC FERNANDEZ; S ERILL; MI LUCENA; E PITA; N PEREZ-ALFEREZ. Serum protein binding of tolbutamide in patients treated with antiepileptic drugs. Clin Pharmacokinet. pp. 451 – 455. 1985.
266 JM BAEYENS; MI LUCENA. Fichas cl.nico-farmacol.gicas: acebutolol, acenocumarol, acetazolamida, acetilcisteina, acetildigitoxina, aciclovir, .cido acetilsalic.lico, actinomicina D, adrenalina, adriamicina, alcaloides dihidrogenados (del cornezuelo de centeno), alopurinol, amantadina, amikacina, amilorida, .cido aminocaproico. Medicine. 3, pp. 1 – 8.. 1984.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
267 MI LUCENA; JM BAEYENS. Fichas cl.nico-farmacol.gicas: aminofilina, aminopirina y otros derivados pirazol.nicos, aminosalic.lico, .cido PAS, amiodarona, amitriptilina, ampicilina-amoxacilina, anfetamina, anfotericina B, Lasparaginasa, atenolol, atropina, azatioprina, azlocilina, baclofen, beclometasona, benzbromarona. Medicine. 9, pp. 1 – 8.. 1984.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
268 JM BAEYENS; MI LUCENA. Fichas cl.nico-farmacol.gicas: betametasona, biperidina-trihexifenidilo, bisacodil, bleomicinna, bretilio, bromocriptina, bumetanida, bupivacaina, buprenorfina, busulfan, calcitonina, captopril, carbamacepina, carbenicilina, carbenoxolona, carmustina (BCNU). Medicine. 15, pp. 1 – 8.. 1984.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
269 MI LUCENA; JM BAEYENS. Fichas cl.nico-farmacol.gicas: cefacetrilo, cefalotina y cefapirina, cefalosporinas activas por via oral, cefaloridina y cefazolina, cefamandol-cefuroxima, cefoperazona y cefotaxima, cefoxitina, ciclofosfamida, cimetidina, cinaricina y flunaricina, ciproheptadina, ciproterona acetato de, cisplatino, citarabina, clebopride, clindamicina y lincomicina, clobazam. Medicine. 18, pp. 1 – 8.. 1984.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
270 JM BAEYENS; MI LUCENA. Fichas cl.nico-farmacol.gicas: clofibrato, clomifeno, clonacepam, clonidina, clorambucil,cloranfenicol, clordiacepoxido, clorfeniramina, cloroquina, clorpromacina, clorpropamida, clortalidona, clotrimazol, cloxacilina, oxacilina, dicloxacilina y flucloxacilina, codeina, colchicina. Medicine. 23, pp. 1 – 8.. 1984.
271 MI LUCENA GONZALEZ. Cumplimiento de la prescripci.n como elemento de respuesta terap.utica. Medicine. 58, pp. 3729 – 3737.. 1983.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
272 W RUPP; M BADIAN; E DAGROSA; F GANSHORN; MI LUCENA; W PETRI; W. SITTIG. Kinetics of UV-erythema in normal subjects. Br J Dermatol. pp. 111 – 113. 1983.
273 MI LUCENA GONZALEZ; JA SOTO MAS; B GIL EXTREMERA. Terap.utica de la meningitis bacteriana. Actualidad M.dica. 667, pp. 27 – 38.. 1983.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
274 MI LUCENA GONZALEZ. Interacciones medicamentosas de la digoxina. Actualidad M.dica. 658, pp. 293 – 304. 1981.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
275 RJ ANDRADE; C MART.NEZ; E ULZURRUN; E GARC.A-MART.N; C STEPHENS; G PELAEZ; M ROMERO-GOMEZ; A CASTIELLA; R PLANAS; C GUARNER; G SORIANO; Y BORRAZ; MI LUCENA; JA. AGUNDEZ. Relevancia del polimorfismo funcional de la manganeso super.xido dismutasa (sod2 val16ala) y de la glutation peroxidasa1 (gpx1 pro200leu) en pacientes con da.o hep.tico idiosincr.sico inducido por medicamentos (DILI). Gastroenterol Hepatol. 33(Espec Congr 1), pp. 108.
Tipo de producción: Art.culo cient.fico Tipo de soporte: Revista
276 ANCA LILIANA CISMARU; DEBORAH RUDIN; LUISA IBA.EZ; EVANGELIA LIAKONI; NICOLAS BONADIES; REINHOLD KREUTZ; ALFONSO CARVAJAL; MARIA ISABEL LUCENA; JAVIER MARTIN; ESTHER SANCHO PONCE; MARIAM MOLOKHIA; NIKLAS ERIKSSON; STEPHAN KR.HENB.HL; CARLO LARGIAD.R; MANUEL HASCHKE; P.R HALLBERG; MIA WADELIUS; URSULA AMSTUTZ.. Genome-wide association study of metamizole-induced agranulocytosis in European populations.Genes (Q2: 54/178). 11 – 11, pp. 1275 – 1275. MDPI, 2020. ISSN 2073-4425 DOI: 10.3390/genes11111275
277 JUDITH SANABRIA-CABRERA; ROC.O SANJU.N-JIM.NEZ; ENCARNACI.N CLAVIJO; INMACULADA MEDINA-C.LIZ; ANDR.S GONZ.LEZ-JIM.NEZ; MIREN GARC.A-CORT.S; AIDA ORTEGA-ALONSO; MIGUEL JIM.NEZ-P.REZ; ROC.O GONZ.LEZ-GRANDE; CAMILLA STEPHENS; MERCEDES ROBLES-D.AZ; M ISABEL LUCENA; RA.L J ANDRADE. Incidence and prevalence of acute hepatitis E virus infection in patients with suspected Drug-Induced Liver Injury in the Spanish DILI Registry. Liver International (Q1: 19/88) IN PRESS. WILEY, 2020. Disponible en Internet en: <https://onlinelibrary.wiley.com/doi/abs/10.1111/liv.14713>. ISSN 1478-3223 DOI: 10.1111/liv.14713
278 M ISABEL LUCENA; ELENA GARC.A-MART.N; ANN K DALY; MIGUEL BLANCA; RA.L J ANDRADE; JOS. A G AG.NDEZ.. Case Report. Next-generation sequencing of PTGS genes reveals an increased frequency of nonsynonymous variants among patients with NSAIDinduced liver injury.Frontiers in 1a9904668551e345a94a72d6c41aacb9 117 Genetics (Q2: 73/177). 10 – article 134, pp. 1 – 8. FRONTIERS MEDIA SA, 2019. Disponible en Internet en: <https://www.frontiersin.org/articles/10.3389/fgene.2019.00134/full>. ISSN 1664-8021 DOI: 10.3389/fgene.2019.00134
279 SANABRIA-CABRERA J; MEDINA-C.LIZ I; STANKEVIČIŪTĖ S; RODR.GUEZ-NICOL.S A; ALMARZATORRES M; LUCENA MI; ANDRADE RJ.. Drug-Induced liver Injury Associated with Severe Cutaneous Hypersensitivity Reactions: A Complex Entity in Need of a Multidisciplinary Approach.Current Pharmaceutical Design (Q3: 179/270 CORRESPONDING AUTHOR). 25 – 36, pp. 3855 – 3871. BENTHAM SCIENCE PUBL LTD, 2019. ISSN 1381-6128 DOI: 10.2174/1381612825666191107161912
280 BESSONE F; LUCENA MI; ROMA MG; STEPHENS C; MEDINA-C.LIZ I; FRIDER B; TSARIKTSIAN G; HERN.NDEZ N; BRUGUERA M; GUALANO G; FASSIO E; MONTERO J; REGGIARDO MV; FERRETTI S; COLOMBATO L; TANNO F; FERRER J; ZENO L; TANNO H; ANDRADE RJ.. Cyproterone acetate induces a wide spectrum of acute liver damage including corticosteroid-responsive hepatitis: report of 22 cases.Liver International (Q1: 18/79). 36 – 2, pp. 302 – 310. WILEY-BLACKWELL, 2016. ISSN 1478-3223 DOI: 10.1111/liv.12899
281 AITHAL GP; WATKINS PB; ANDRADE RJ; LARREY D; MOLOKHIA M; TAKIKAWA H; HUNT CM; WILKE RA; AVIGAN M; KAPLOWITZ N; BJORNSSON E; DALY AK. Case Definition and Phenotype Standardisation in Drug-Induced Liver Injury (DILI). Clin Pharmacol Ther. 86 – 6, pp. 806 – 815. WILEYBLACKWELL, 2011. ISSN 0009-9236 DOI: 10.1038/clpt.2011.58
282 CAMILLA STEPHENS; MI. LUCENA; RAUL J ANDRADE. Host Risk Modifiers in Idiosyncratic Drug-Induced Liver Injury (DILI) and Its Interplay with Drug Properties. Drug-Induced Liver Toxicity. pp. 477 – 496. New-York(Estados Unidos de Am.rica): Humana Press, 2018. Disponible en Internet en: <https://link.springer.com/protocol/10.1007/978-1-4939-7677-5_23>. ISSN 1557-2153, ISBN 978-1-4939-7676-8 DOI: https://doi.org/10.1007/978-1-4939-7677-5
283 STEPHENS C.; LUCENA MI; ANDRADE RJ.. Pharmacogenomics and clinical assessment of druginduced hepatotoxicity toward improving clinical outcomes.Handbook of personalized medicine: Advances in nanotechnology, drug delivery and therapy.27, pp. 1293 – 1334. Vizirianakis IS (ed), 2014. ISBN 978- 9-81-441119-6 Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
284 LUCENA MI; STEPHENS C.; GARC.A-CORTES M; ANDRADE RJ. “Causality Assessment”. DRUGINDUCED LIVER DISEASE, Third edition. 18, ELSEVIER, 2013. ISBN 978-0-12-387817-5
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
285 Maria Isabel Lucena; Camilla Stephens; M. Garcia Cortes; Raul J. Andrade. Causality Assessment. druginduced liver disease, third edition. : Neil Kaplowitz and Laurie D. DeLeve, 2011.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
286 Camilla Stephens; Maria Isabel Lucena; Ra.l J. Andrade. Pharmacogenomics and Clinical Assessment of Drug-Induced Hepatotoxicity: toward Improving Clinical Outcomes. Handbook of Personalized Medicine: Advances in Nanotechnology, Drug Delivery and Therapy. 2011.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
287 Ra.l J. Andrade; Maria Isabel Lucena. Drug induced liver disease-Mechanisms and diagnosis; C.pitulo 47. Evidence-Based Gastroenterology and Hepatology. 978-1-4051-8275-1, pp. 771 – 786. Blackwell Ed. 2010, 2010. Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
288 Maria Isabel Lucena; Ra.l J. Andrade. Hepatotoxicidad y nefrotoxicidad por medicamentos; C.pitulo 72. Farmacolog.a b.sica y cl.nica. 978-84-9835-168-2, medical Panamericana, 2008.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
289 Maria Isabel Lucena; Ra.l J. Andrade; R. Camargo; M. Garcia Cortes. Causality assessment. Druginduced Liver Disease 2.. 10:0-8493-9896-7, pp. 325 – 344. New York Informa-Healthcare, 2007.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
290 Raul J. Andrade; Maria Isabel Lucena. Clinical presentations of drug-induced hepatotoxicity and systematic approach to diagnosis in clinical practice. Internacional Hepatology Updates: Hepatotoxicity. 978-84-96762-30-5, pp. 57 – 76. Permanyer Publications, 2007. 1a9904668551e345a94a72d6c41aacb9 119
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
291 Raul J. Andrade; Maria Isabel Lucena. Medicamentos e Higado, capitulo 18. Enfermedades Hep.ticas. Consejos pr.cticos. AEEH.978-84-96762-19-0, pp. 155 – 160. Publicaciones Permanyer, 2007.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
292 E. Martin Aurioles; J.A. Gonz.lez Correa; I. Bellido; Maria Isabel Lucena. Otros antibi.ticos: glucop.ptidos, lincosaminas,oxazolidinonas y estreptograminas, capitulo 51. Farmacolog.a en Enfermer.a. 978848174993-9, pp. 441 – 446. Elsevier, 2007.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
293 Maria Isabel Lucena. Unidad did.ctica 32. Patolog.a Neumol.gica. ACTUALIZACION EN MEDICINA GENERAL Y DE FAMILIA. Consejo General de Colegio Oficiales de M.dicos, 2007.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
294 Ra.l J. Andrade; Maria Isabel Lucena. Hepatitis t.xica. Problemas comunes en la pr.ctica cl.nica. Gastroenterolog.a y Hepatolog.a. pp. 581 – 592. Jarpyo Editores. Asociaci.n Espa.ola de Gastroenterolog.a/ Asociaci.n Espa.ola para el Estudio del H.gado, 2006.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
295 Ra.l J. Andrade; F.J. Salmeron; Maria Isabel Lucena. Drug Hepatotoxicity. The Clinician’s Guide to Liver Disease. ISBN: 1-55642-6755, SLACK Incorporated, 2005.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
296 Maria Isabel Lucena. Unidad did.ctica 32. Patolog.a Neumol.gica. ACTUALIZACION EN MEDICINA GENERAL Y DE FAMILIA. Consejo General de Colegio Oficiales de M.dicos, 2005.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
297 Ra.l J. Andrade; Maria Isabel Lucena. Enfermedades hep.ticas secundarias a medicamentos. Medicina Interna 2. ed. pp. 1470 – 1477. Masson, 2004.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
298 Ra.l J. Andrade; Maria Isabel Lucena; m. Rosario Cabello. Enfermedades hep.ticas secundarias a medicamentos y a t.xicos de origen ambiental o industrial. Manual de Patolog.a Digestiva. 2 – ISBN: 84-338-3055-4, pp. 863 – 877. Editorial Universidad de Granada, 2004.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
299 Ra.l J. Andrade; M. Garcia Cortes; R. Gonzalez Grande; Maria Isabel Lucena; J.V. Martos; E. Fernandez Bonilla; R. Alcantara. Hepatotoxic effects of immunotherapy. Immunology and the liver: Immunotherapy. pp. 25 – 33. Acci.n M.dica, 2004.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
300 Maria Isabel Lucena; J.A. Gonz.lez Correa; Ra.l J. Andrade. Utilizaci.n de f.rmacos en pacientes con alteraciones respiratorias, digestivas o inmunitarias. Farmacolog.a B.sica y Cl.nica. Panamericana, 2004. Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
301 Ra.l J. Andrade; Maria Isabel Lucena; M. Garcia Cortes. Hepatitis T.xicas. De los signos y s.ntomas al diagn.stico y tratamiento en Patolog.a Digestiva. Sugesti.n Gr.fica, 2003.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
302 Maria Isabel Lucena. Unidad did.ctica 32. Patolog.a Neumol.gica. ACTUALIZACION EN MEDICINA GENERAL Y DE FAMILIA. Consejo General de Colegio Oficiales de M.dicos, 2003.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
303 J. Benitez Rodriguez; Maria Isabel Lucena Gonz.lez; J.A. Carrillo; M.R. Cabello. Factores fisiol.gicos que condicionan la respuesta a los f.rmacos I: causas gen.ticas, ambientales y diet.ticas. Manual del Residente de Farmacolog.a Cl.nica. LITOFINTER, S.A, 2002.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
304 J.A. Gonz.lez Correa; MR Cabello Porras; E Blanco Reina; A. Gomez Outes; Maria Isabel Lucena; F. Sanchez de la Cuesta. Factores patol.gicos que condicionan la respuesta a los f.rmacos. Manual del Residente de Farmacolog.a Cl.nica. pp. 407 – 440. LITOFINTER, S.A, 2002.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
305 Raul J. Andrade; Maria Isabel Lucena. Hepatitis t.xica. Manual de Terap.utica M.dica. pp. 401 – 410. Masson S.A, 2002.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
306 R. Alcantara; Raul J. Andrade; Maria Isabel Lucena. Lesiones hep.ticas provocadas por f.rmacos. Gastroenterolog.a y Hepatolog.a. pp. 663 – 673. Berenguer J, Berenguer M, Ponce J, Prieto M, Sala T eds, 2002. Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
307 J.A. Gonz.lez Correa; Maria Isabel Lucena Gonz.lez; J. Pavia Molina. Antibi.ticos beta-lact.micos (II): Cefalosporinas. Farmacolog.a en Enfermer.a. Castells S, Hern.ndez M eds. Ediciones Harcourt, 2001. Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
308 Ra.l J. Andrade; Maria Isabel Lucena; R. Camargo. Hepatitis medicamentosas y t.xicas. Tratamiento de las Enfermedades Hep.ticas.pp. 75 – 89. Berenguer J, Bruguera M, Bengoechea M, Rodrigo-Saez L eds., 2001. Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
309 Maria Isabel Lucena. Unidad did.ctica 32. Patolog.a Neumol.gica. ACTUALIZACION EN MEDICINA GENERAL Y DE FAMILIA. Consejo General de Colegio Oficiales de M.dicos, 1999. Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
310 Maria Isabel Lucena. Problemas y controversias en torno al ensayo cl.nico. Monografias Dr. A. Esteve n.22. pp. 83 – 93. 1998.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
311 Ra.l J. Andrade; Maria Isabel Lucena. Hepatitis t.xicas. Tratamiento de las Enfermedades Hep.ticas. pp. 201 – 210. Bruguera M, Mi.o G, Pons F, Moreno R eds., 1997.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
312 Maria Isabel Lucena. Nutrici.n y F.rmacos. Modificaciones en la cin.tica de los f.rmacos inducidos por la obesidad. La obesidad: Tratamiento m.dico y procedimientos quir.rgicos. I.S.B.N. : 84-7496-6, Garcia-Caballero M, Morell M eds, 1996.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
313 Maria Isabel Lucena; S. Anaya; E. Calero; E. Heredia; F. Merida; F. Pajares. Tratamiento del dolor y la inflamaci.n en las enfermedades osteo-articulares. Recomendaciones Farmacoterap.uticas,. 5, Junta de Andaluc.a. Consejer.a de Salud, 1994.
314 A. Moreno Gonzalez; Maria Isabel Lucena G.nzalez. Farmacolog.a Cl.nica: Ensayo cl.nico.Velazquez. Farmacolog.a. ISBN 84-7615-958-7, Editorial Interamericana. McGraw-Hill, 1993.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
315 Ra.l J. Andrade; Maria Isabel Lucena; J.A. Gonzalez Correa; C. Garcia Arias; R. Hidalgo; P. Gonzalez Santos. Effect of low doses of cyclosporin A on lipid profile and its distribution among plasma lipoproteins in the rat. Molecular Biology of Atherosclerosis, Proceedings of the 57th European Congress of Atherosclerosis. pp. 369 – 372. Halpern MJ. John Libbey Company Ltd, 1992. Tipo de producción: Cap.tulo de libro Tipo de soporte: Documento o Informe cient.fico-t.cnico
316 Maria Isabel Lucena Gonz.lez. Interacciones Medicamentosas. El Manual de Medicina. Salvat, 1992. Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
317 Cumplimiento de la medicaci.n. Lecciones del II Curso de Terap.utica Aplicada. pp. 35 – 55. Ministerio de Sanidad y Consumo. Direcci.n General de Farmacia y Productos, 1988.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
318 Maria Isabel Lucena Gonz.lez; A. Moreno Gonz.lez. Farmacolog.a Cl.nica: ensayo cl.nico. Farmacolog.a y su proyecci.n a la Cl.nica. Editorial Oteo, 1987.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
319 F. Martos; J.A. Gomez; A Garrido; Maria Isabel Lucena; F. Sanchez de la Cuesta. Uso de benzodiacepinas en los trastornos del sue.o. Benzodiacepinas y sue.o. 1985.
Tipo de producción: Cap.tulo de libro Tipo de soporte: Libro
320 Maria Isabel Lucena; E. Blanco; I. Bellido. FARMACOLOG.A CL.NICA. PREGUNTAS TIPO TEST COMENTADAS. VERSI.N 2006-2007. FARMACOLOG.A CL.NICA. PREGUNTAS TIPO TEST COMENTADAS. VERSI.N 2006-2007. 978-84-691-0996-0, Departamento de Farmacolog.a. Facultad de Medicina, 2006.
Tipo de producción: Libro o monograf.a cient.fica Tipo de soporte: Libro
321 Raul J. Andrade; R. Camargo; M.D. Garcia Esca.o; R. Alcantara; M. Garcia Cortes; E. Garcia Ruiz; EM Fernandez Bonilla; Maria Isabel Lucena. Hepatopat.as t.xicas. Hepatopat.as t.xicas. ISBN: 84-7429-125-9, Editorial Glosa, 2002.
Tipo de producción: Libro o monograf.a cient.fica Tipo de soporte: Libro
322 EASL Clinical Practice Guideline: Occupational liver diseases.Journal of Hepatology (D1: 2/88, Panel member). 71 – 5, pp. 1022 – 1037. ELSEVIER SCIENCE BV, 2019. ISSN 0168-8278 DOI: 10.1016/j.jhep.2019.08.008
323 HAO NIU; JUDITH SANABRIA-CABRERA; ISMAEL ALVAREZ-ALVAREZ; MERCEDES ROBLES-DIAZ; SIMONA STANKEVIČIŪTĖ; GURUPRASAD P AITHAL; EINAR S BJ.RNSSON; RAUL J ANDRADE; M ISABEL LUCENA. Prevention and management of idiosyncratic drug-induced liver injury: Systematic review and meta-analysis of randomised clinical trials. Pharmacological Research (D1: 19/271) CORRESPONDING AUTHOR. 164, pp. 105404. ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD, 2021. ISSN 1043-6618 DOI: 10.1016/j.phrs.2020.105404
324 MIREN GARCIA-CORTES; MERCEDES ROBLES-DIAZ; CAMILLA STEPHENS; AIDA ORTEGAALONSO; M. ISABEL LUCENA; RA.L J. ANDRADE. Drug induced liver injury: an update. Archives of Toxicology (D1: 9/92). 94 – 10, pp. 3381 – 3407. SPRINGER HEIDELBERG, 2020. ISSN 0340-5761 DOI: https://doi.org/10.1007/s00204-020-02885-1
325 M ISABEL LUCENA; JUDITH SANABRIA; MIREN GARCIA-CORTES; CAMILLA STEPHENS; RAUL J ANDRADE.. Review. Drug-Induced Liver Injury in older people.Lancet Gastroenterology & Hepatology (D1: 5/88). CORRESPONDING AUTHOR. 5 – 9, pp. 862 – 874. ELSEVIER INC, 2020. DOI: 10.1016/S2468-1253(20)30006-6
326 ROBLES-DIAZ M; MEDINA-C.LIZ I; ANDRADE RJ; LUCENA MI. Reply letter to “Editorial: bodybuilders beware”.Alimentary Pharmacology & Therapeutics (D1: 11/270). 50 – 4, pp. 473 – 473. WILEY, 2019. ISSN 0269-2813 DOI: 10.1111/apt.15400
327 ANDRADE RJ; CHALASANI N; BJ.RNSSON ES; SUZUKI A; KULLAK-UBLICK GA; WATKINS PB; DEVARBHAVI H; MERZ M; LUCENA MI; KAPLOWITZ N; AITHAL GP.. Review. Drug-induced liver injury.Nature Reviews Disease Primers (D1: 4/165; CORRESPONDING AUTHOR). 5 – 1, pp. 58 – 58. NATURE PUBLISHING GROUP, 2019. ISSN 2056-676X DOI: 10.1038/s41572-019-0105-0
328 Slim M; Ruiz-Cabello E; Robles-D.az M; Lucena MI; Andrade RJ. A New Hepatoprotective Effect of Statins: Are They Always Safe for the Liver?. Am J Gastroenterology (D1, 6 of 80). 112 – 2, pp. 384 – 385. NATURE PUBLISHING GROUP, 2017. ISSN 0002-9270 DOI: 10.1038/ajg.2016.448
329 Andrade RJ; Lucena MI; Robles-D.az M; Medina-C.liz I. Drug-induced liver and skin reactions: In need of a consensus definition.Hepatology (D1: 5/80). 65 – 1, pp. 391 – 391. WILEY-BLACKWELL, 2017. ISSN 0270-9139 DOI: 10.1002/hep.28808
330 Inmaculada Medina-C.liz; Mercedes Robles-D.az; M. Isabel Lucena; Ra.l J. Andrade. Letter to the editor. Drug-induced liver and skin reactions: In need of a consensus definition.Hepatology (D1, 5 of 80). 65 – 1, pp. 391 – 391. (Estados Unidos de Am.rica): WILEY, 2017. ISSN 0270-9139 DOI: 10.1002/hep.28808
331 RA.L J. ANDRADE; AIDA ORTEGA-ALONSO; MAR.A ISABEL LUCENA. Editorial. Drug-Induced Liver Injury Clinical Consortia: a global research response for a worldwide health challenge.Expert Opinion on Drug Metabolism & Toxicology. 12 – 6, pp. 589 – 593. INFORMA HEALTHCARE, 2016. ISSN 1742-5255 DOI: 10.1517/17425255.2016.1141896
332 ULZURRUN E.; STEPHENS C.; RUIZ-CABELLO F.; ROBLES-DIAZ M.; SAENZ-L.PEZ P.; HALLAL H.; SORIANO G.; ROMAN E.; FERNANDEZ MC; LUCENA MI.; ANDRADE RJ.. CORRECTION: Selected ABCB1, ABCB4 and ABCC2 Polymorphisms Do Not Enhance the Risk of Drug-Induced Hepatotoxicity in a Spanish Cohort.PLoS One (Q1: 11/63) CORRESPONDING AUTHOR. 10 – 10, pp. e0141400 – e0141400. PUBLIC LIBRARY SCIENCE, 2015. ISSN 1932-6203 DOI: 10.1371/journal.pone.0141400
333 ROBLES-DIAZ M.; KAPLOWITZ N.; STEPHENS C.; ANDRADE RJ; LUCENA MI.. Reply. Refers to: Aylin Tansel, Fasiha Kanwal, F. Blaine Hollinger. Use of Hy’s Law, R Criteria, and nR Criteria to Predict Acute Liver Failure or Transplantation in Patients With Drug-Induced Liver Injury. Gastroenterology (D1: 1/79). 148 – 2, pp. 452 – 453. W B SAUNDERS CO-ELSEVIER INC, 2015. ISSN 0016-5085
334 SANTOS G; GASCA J; PARANA R; NUNES V; SCHINNONI M; MEDINA-CALIZ I; CABELLO MR; LUCENA MI; ANDRADE RJ.. Review. Profile of herbal and dietary supplements induced liver injury in Latin America: A systematic review of published reports.Phytotherapy Research (Q1: 58/270). 35 – 1, pp. 6 – 19. WILEY, 2021. ISSN 0951- 418X DOI: 10.1002/ptr.6746
335 RJ ANDRADE; MI LUCENA; N KAPLOWITZ. How common is chronic liver disease from acute drug induced liver injury? Reply. Gastroenterology. 132 – 5, pp. 2068 – 2069. 2007.
336 Maria Isabel Lucena. PREFACIO. Business Briefing: EuropeanPharmacoTherapy. 2004. Tipo de producción: Prefacio
337 CAMILLA STEPHENS; M ISABEL LUCENA; RA.L J ANDRADE. Genetic risk factors in the development of idiosyncratic drug-induced liver injury. Expert Opinion on Drug Metabolism & Toxicology (Q2: 24/92). 17 – 2, pp. 153 – 169. TAYLOR & FRANCIS LTD, 2021. ISSN 1742-5255 DOI: 10.1080/17425255.2021.1854726
338 BESSONE F; ROBLES-DIAZ M; HERNANDEZ N; MEDINA-CALIZ I; LUCENA MI; ANDRADE RJ.. Review. Assessment of Serious Acute and Chronic Idiosyncratic Drug-Induced Liver Injury in Clinical Practice.Seminars in Liver Disease (Q2: 25/88). 39 – 3, pp. 381 – 394. THIEME MEDICAL PUBL INC, 2019. ISSN 0272-8087 DOI: 10.1055/s-0039-1685519
339 Mahmoud Slim; INMACULADA MEDINA-CALIZ; ANDRES GONZALEZ-JIMENEZ; M ROSARIO CABELLO; FERMIN MAYORAL-CLERIES; M ISABEL LUCENA; RAUL J ANDRADE. Review. Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.Drug Safety (Q1, 29 of 176). 39 – 10, pp. 925 – 943. 2016. ISSN 0114-5916 DOI: 10.1007/s40264-016-0436-7
340 Robles-diaz M.; MEDINA-C.LIZ I; STEPHENS C; ANDRADE RJ; LUCENA MI. Review. Biomarkers in DILI: one more step forward. Frontiers in Pharmacology22 – 7, pp. 267 – 267. (Position 5 of 5, senior), 2016. ISSN 1663-9812 DOI: 10.3389/fphar.2016.00267
341 Bessone F; Hernandez N; Roma MG; Ridruejo E; Mendizabal M; Medina- C.liz I; Robles-D.az M; Lucena MI; Andrade RJ. Review. Hepatotoxicity induced by coxibs: how concerned should we be?. Expert Opinion on Drug Safety (Q1: 63 of 257). 15 – 11, pp. 1463 – 1475. INFORMA HEALTHCARE, 2016. ISSN 1474-0338 DOI: 10.1080/14740338.2016.1225719
342 BESSONE F; HERNANDEZ N; LUCENA MI; ANDRADE RJ. Review. The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative.International Journal of Molecular Sciences (Q2: 74/297). 17 – 3, pp. E313 – E313. MDPI AG, 2016. ISSN 1422-0067 DOI: 10.3390/ijms17030313
343 Maria Isabel Lucena; G. Tognoni; F. Sanchez de la Cuesta. Comit.s .ticos de investigaci.n cl.nica: nuevas funciones para un nuevo escenario. Aspectos conceptuales del Ensayo Cl.nico. F Bosch ed, 2000. Tipo de soporte: Revista
[/wm_item][/wm_tabs][/vc_column][/vc_row]